

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	FEB 15	RUSSIAPAT enhanced with pre-1994 records

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:55:20 ON 16 FEB 2007

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:55:32 ON 16 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 FEB 2007 HIGHEST RN 921041-62-5
DICTIONARY FILE UPDATES: 14 FEB 2007 HIGHEST RN 921041-62-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10481728c.str



```

chain nodes :
10 11 19
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
2-11 4-10 7-19 8-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
1-2 1-6 2-3 2-11 3-4 4-5 4-10 5-6 5-7 6-9 7-8 7-19 8-9
exact bonds :
8-12
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17

```

G1:H,Cy,Ak,C

G2:C,H,OH,Cy,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS. NO ANSWERS

L1 STR



G1 H, Cy, Ak, C
G2 C, H, OH, Cy, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s k1 sam
SAMPLE IS IGNORED AS A SCOPE FOR THIS SEARCH
L2 24880 K1

=> s l1 sam
SAMPLE SEARCH INITIATED 08:55:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 142 TO ITERATE

100.0% PROCESSED 142 ITERATIONS 40 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2126 TO 3554
PROJECTED ANSWERS: 421 TO 1179

L3 40 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 08:56:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2771 TO ITERATE

100.0% PROCESSED 2771 ITERATIONS 836 ANSWERS
SEARCH TIME: 00.00.01

L4 836 SEA SSS FUL L1

=> fil capl		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	177.50	177.71

FILE 'CAPLUS' ENTERED AT 08:56:26 ON 16 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.

FILE COVERS 1907 - 16 Feb 2007. VOL 146 ISS 9
 FILE LAST UPDATED: 15 Feb 2007 (20070215/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
 They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 14

L5 34 L4

=> s 15 not (2006/so or 2005/so)

788844 2006/SO

867444 2005/SO

L6 30 L5 NOT (2006/SO OR 2005/SO)

=> d 16 ibib hitstr abs 1-34

L6 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:552968 CAPLUS

DOCUMENT NUMBER: 143:38403

TITLE: Method of treating ischemia reperfusion injury using
 adenosine receptor antagonists

INVENTOR(S): Smits, Glenn J.; Jin, Xiaowei; Gross, Garrett J.;
 Auchampach, John

PATENT ASSIGNEE(S): Biogen, Inc., USA; The MCW Research Foundation, Inc.

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003105666	A2	20031224	WO 2003-US18695	20030612
WO 2003105666	A3	20040916		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2489179	A1	20031224	CA 2003-2489179	20030612
AU 2003236509	A1	20031231	AU 2003-236509	20030612
EP 1513848	A2	20050316	EP 2003-737066	20030612
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003012137	A	20050405	BR 2003-12137	20030612
CN 1671716	A	20050921	CN 2003-817433	20030612
JP 2005533054	T	20051104	JP 2004-512582	20030612
NZ 537444	A	20060929	NZ 2003-537444	20030612

US 2005203065 A1 20050915 US 2004-6022 20041206
 NO 2005000149 A 20050311 NO 2005-149 20050111
 PRIORITY APPLN. INFO.: US 2002-388680P P 20020612
 WO 2003-US18695 W 20030612


OTHER SOURCE(S): MARPAT 143:38403

IT 853235-58-2

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (method of treating ischemia reperfusion injury using adenosine
 receptor antagonists)

RN 853235-58-2 CAPLUS

CN Benzonitrile, 4-(2,3,4,5-tetrahydro-7-hydroxy-2,4-dioxo-1,3-dipropyl-1H-
 pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)



AB Methods useful for preventing, limiting, or treating ischemia reperfusion
 injury in a mammal are disclosed. More particularly, this invention
 relates to administering A2b adenosine receptor antagonists to prevent,
 limit or treat ischemia reperfusion injury.

L6 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:965256 CAPLUS

DOCUMENT NUMBER: 141:410951

TITLE: Preparation of fused pyrimidine derivatives for
 treatment of diabetes

INVENTOR(S): Nakajima, Takao; Ueno, Kimihisa; Nomoto, Yuji;
 Matsumoto, Yuichi; Yano, Hiroshi; Nakanishi, Satoshi;
 Takasaki, Kotaro; Kusaka, Hideaki

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096812	A1	20041111	WO 2004-JP5890	20040423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004234245	A1	20041111	AU 2004-234245	20040423
CA 2523763	A1	20041111	CA 2004-2523763	20040423
EP 1637532	A1	20060322	EP 2004-729197	20040423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 CN 1777608 A 20060524 CN 2004-80010487 20040423
 US 2006252780 A1 20061109 US 2005-554254 20051024
 PRIORITY APPLN. INFO.: JP 2003-121287 A 20030425
 WO 2004-JP5890 W 20040423


OTHER SOURCE(S): MARPAT 141:410951

IT 791071-49-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of fused pyrimidine derivs. for treatment of
 diabetes)

RN 791071-49-3 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-phenyl-1-propyl- (9CI)
 (CA INDEX NAME)



GI



I



II

AB The title fused pyrimidine derivs. represented by the formula I [wherein
 R1 = H, (un)substituted alkyl, aralkyl, aryl, or heteroaryl; n = 0-3; X1
 and X2 = independently H, (un)substituted alkyl, aralkyl, aryl, or
 heteroaryl; ring A = pyrrole, pyrazole, etc.] and pharmaceutically
 acceptable salts thereof are prepared for the treatment of diabetes. For
 example, the compound II was prepared in a multi-step synthesis. I showed
 significant promoting effect on insulin secretory activity at the concentration
 of 1.0 μ M.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:815641. CAPLUS

DOCUMENT NUMBER: 142:6485

TITLE: 8-Substituted-9-deazaxanthines as adenosine receptor
 ligands: design, synthesis and structure-affinity
 relationships at A2B

AUTHOR(S): Carotti, Angelo; Stefanachi, Angela; Ravina, Enrique;
 Sotelo, Eddy; Loza, Maria Isabel; Cadavid, Maria
 Isabel; Centeno, Nuria B.; Nicolotti, Orazio

CORPORATE SOURCE: Dipartimento Farmacochimico, Universita di Bari, Bari,

70125, Italy
 SOURCE: European Journal of Medicinal Chemistry (2004),
 39(10), 879-887
 CODEN: EJMCA5; ISSN: 0223-5234
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:6485


IT 59119-44-7P 798542-22-0P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation, adenosine receptor binding affinity, and structure-affinity relationship of aryldeazaxanthines using condensation of dialkyl(methyl)nitrouracils with arylaldehyde and heterocyclization as the key steps)


RN 59119-44-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI)
 (CA INDEX NAME)



RN 798542-22-0 CAPLUS

CN Acetamide, N-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]- (9CI) (CA INDEX NAME)




IT 157119-67-0P 157119-69-2P 548943-27-7P
 548943-90-4P 798542-20-8P 798542-21-9P
 798542-23-1P 798542-24-2P 798542-31-1P
 798542-32-2P 798542-33-3P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation, adenosine receptor binding affinity, and structure-affinity relationship of aryldeazaxanthines using condensation of dialkyl(methyl)nitrouracils with arylaldehyde and heterocyclization as the key steps)

RN 157119-67-0 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3,5-trimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 157119-69-2 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-phenyl-1,3-dipropyl- (9CI)
 (CA INDEX NAME)




RN 548943-27-7 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-6-phenyl-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-90-4 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-methoxyphenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 798542-20-8 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-hydroxyphenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 798542-21-9 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-aminophenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 798542-23-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(2-fluorophenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 798542-24-2 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(2,6-difluorophenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 798542-31-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-aminophenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 798542-32-2 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-propoxyphenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)



RN 798542-33-3 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(phenylmethoxy)phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)



GI



AB A number of 8-substituted 9-deazaxanthines, e.g., I, were prepared and tested for their antagonistic activity at the recombinant human adenosine receptors, in particular at the A2B and A2A receptor subtypes. Compds. endowed with micromolar to nanomolar binding affinities, but with poor A2B/A2A selectivity, were obtained. Preliminary quant. structure-affinity relationships suggested that the binding potency at the A2B receptor is mainly modulated by the electronic and lipophilic properties of the ligands.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:796708 CAPLUS
DOCUMENT NUMBER: 139:307790
TITLE: Preparation of new 4-(pyrrolopyrimidin-6-yl)benzenesulfonamides as A2A and/or A2B adenosine receptor selective antagonists
INVENTOR(S): Vidal Juan, Bernat; Esteve Trias, Cristina
PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082873	A1	20031009	WO 2003-EP3378	20030401
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
ES 2208063	A1	20040601	ES 2002-752	20020401
ES 2208063	B1	20051001		
AU 2003215680	A1	20031013	AU 2003-215680	20030401
EP 1492793	A1	20050105	EP 2003-745198	20030401
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005526817	T	20050908	JP 2003-580338	20030401
US 2005261248	A1	20051124	US 2005-509280	20050505
PRIORITY APPLN. INFO.:			ES 2002-752	A 20020401
			WO 2003-EP3378	W 20030401

OTHER SOURCE(S): MARPAT 139:307790
IT 612093-24-0P 612093-25-1P 612093-26-2P
612093-27-3P 612093-28-4P 612093-29-5P
612093-30-8P 612093-31-9P 612093-32-0P
612093-33-1P 612093-34-2P 612093-35-3P
612093-36-4P 612093-37-5P 612093-38-6P
612093-39-7P 612093-40-0P 612093-41-1P
612093-42-2P 612093-43-3P 612093-45-5P
612093-46-6P 612093-47-7P 612093-48-8P
612093-49-9P 612093-50-2P 612093-51-3P
612093-52-4P 612093-53-5P 612093-54-6P
612093-55-7P 612093-56-8P 612093-57-9P
612093-58-0P 612093-59-1P 612093-60-4P
612093-61-5P 612093-62-6P 612093-63-7P
612093-64-8P 612093-65-9P 612093-66-0P
612093-67-1P 612093-68-2P 612093-69-3P
612093-70-6P 612093-71-7P 612093-72-8P
612093-73-9P 612093-74-0P 612093-75-1P
612093-76-2P 612093-77-3P 612093-78-4P
612093-79-5P 612093-80-8P 612093-81-9P
612093-82-0P 612093-83-1P 612093-84-2P
612093-85-3P 612093-86-4P 612093-87-5P


612093-88-6P 612093-89-7P 612093-90-0P
 612093-91-1P 612093-92-2P 612093-93-3P
 612093-94-4P 612093-95-5P 612093-96-6P
 612093-97-7P 612093-98-8P 612093-99-9P
 612094-00-5P 612094-01-6P 612094-02-7P
 612094-03-8P 612094-04-9P 612094-05-0P
 612094-06-1P 612094-07-2P 612094-08-3P
 612094-09-4P 612094-10-7P 612094-11-8P
 612094-12-9P 612094-13-0P 612094-14-1P
 612094-15-2P 612094-16-3P 612094-17-4P
 612094-18-5P 612094-19-6P 612094-20-9P
 612094-21-0P 612094-22-1P 612094-23-2P
 612094-24-3P 612094-25-4P 612094-26-5P
 612094-27-6P 612094-28-7P 612094-29-8P
 612094-30-1P 612094-31-2P 612094-32-3P
 612094-33-4P 612094-35-6P 612094-36-7P
 612094-37-8P 612094-38-9P 612094-40-3P
 612094-41-4P 612094-42-5P 612094-43-6P
 612094-44-7P 612094-45-8P 612094-46-9P
 612094-47-0P 612094-48-1P 612094-49-2P
 612094-50-5P 612094-51-6P 612094-52-7P
 612094-53-8P 612094-54-9P 612094-55-0P
 612094-56-1P 612094-57-2P 612094-58-3P
 612094-59-4P 612094-60-7P 612094-61-8P
 612094-62-9P 612094-63-0P 612094-64-1P
 612094-65-2P 612094-66-3P 612094-67-4P
 612094-68-5P 612094-69-6P 612094-70-9P
 612094-71-0P 612094-72-1P 612094-73-2P
 612094-74-3P 612094-75-4P 612094-76-5P
 612094-77-6P 612094-78-7P 612094-79-8P
 612094-80-1P 612094-81-2P 612094-82-3P
 612094-83-4P 612094-84-5P 612094-85-6P
 612094-86-7P 612094-87-8P 612094-88-9P
 612094-89-0P 612094-90-3P 612094-91-4P
 612094-92-5P 612094-93-6P 612094-94-7P
 612094-95-8P 612094-96-9P 612094-97-0P
 612094-98-1P 612094-99-2P 612095-00-8P
 612095-01-9P 612095-02-0P 612095-03-1P
 612095-04-2P 612095-05-3P 612095-06-4P
 612095-07-5P 612095-08-6P 612095-09-7P
 612095-10-0P 612095-11-1P 612095-12-2P
 612095-13-3P 612095-14-4P 612095-15-5P
 612095-16-6P 612095-17-7P 612095-18-8P
 612095-19-9P 612095-20-2P 612095-21-3P
 612095-22-4P 612095-23-5P 612095-24-6P
 612095-25-7P 612095-27-9P 612095-28-0P
 612095-30-4P 612095-32-6P 612095-33-7P
 612095-35-9P 612095-36-0P 612095-37-1P
 612095-38-2P 612095-39-3P 612095-40-6P
 612095-41-7P 612095-42-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(preparation of new 4-(pyrrolopyrimidin-6-yl)benzenesulfonamides as A2A
 and/or A2B adenosine receptor selective antagonists)

RN 612093-24-0 CAPLUS


CN Piperazine, 1-(phenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-
 dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX
 NAME)




RN 612093-25-1 CAPLUS
 CN Piperazine, 1-[(4-fluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-26-2 CAPLUS
 CN Piperazine, 1-[(3-fluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-27-3 CAPLUS
 CN Piperazine, 1-[(2,4-difluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-28-4 CAPLUS
 CN Piperazine, 1-[(2-fluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-29-5 CAPLUS
 CN Piperazine, 1-[(4-chlorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-30-8 CAPLUS
 CN Piperazine, 1-[(3-chlorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-31-9 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-32-0 CAPLUS
 CN Piperazine, 1-[(2-bromophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-33-1 CAPLUS
 CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612093-34-2 CAPLUS
 CN Piperazine, 1-[[4-(1,1-dimethylethyl)phenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 612093-35-3 CAPLUS
 CN Piperazine, 1-[(4-methoxyphenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-36-4 CAPLUS
 CN Piperazine, 1-[(3-methoxyphenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-37-5 CAPLUS

CN Piperazine, 1-(1,3-benzodioxol-5-ylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
(CA INDEX NAME)




RN 612093-38-6 CAPLUS

CN Piperazine, 1-[(4-cyanophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
(CA INDEX NAME)




RN 612093-39-7 CAPLUS


CN Piperazine, 1-(3-furanylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-40-0 CAPLUS
 CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(2-thienylmethyl)- (9CI)
 (CA INDEX NAME)




RN 612093-41-1 CAPLUS
 CN Piperazine, 1-[(5-chloro-2-thienyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612093-42-2 CAPLUS
 CN Piperazine, 1-(4-pyridinylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-43-3 CAPLUS
 CN Piperazine, 1-(1-phenylethyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-45-5 CAPLUS
 CN 1H-1,4-Diazepine, hexahydro-1-(phenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-46-6 CAPLUS
 CN 1H-1,4-Diazepine, 1-[(4-fluorophenyl)methyl]hexahydro-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-47-7 CAPLUS
 CN Piperazine, 1-(3-phenyl-2-propenyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 612093-48-8 CAPLUS
 CN 2,5-Diazabicyclo[2.2.1]heptane, 2-(phenylmethyl)-5-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-49-9 CAPLUS
 CN Piperazine, 1-(diphenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-50-2 CAPLUS

CN Benzenesulfonamide, N-[2-[methyl(phenylmethyl)amino]ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI)
(CA INDEX NAME)




RN 612093-51-3 CAPLUS

CN Piperazine, 1-(2-pyridinyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-52-4 CAPLUS

CN Piperazine, 1-(5-methoxy-4-pyrimidinyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
(CA INDEX NAME)




RN 612093-53-5 CAPLUS

CN Benzenesulfonamide, N-[1-(phenylmethyl)-4-piperidinyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI)
(CA INDEX NAME)




RN 612093-54-6 CAPLUS

CN Benzenesulfonamide, N-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612093-55-7 CAPLUS

CN Benzenesulfonamide, N-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612093-56-8 CAPLUS

CN Benzenesulfonamide, 4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[1-(2-thienylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612093-57-9 CAPLUS

CN Benzenesulfonamide, N-methyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI)
(CA INDEX NAME)




RN 612093-58-0 CAPLUS

CN Benzenesulfonamide, N-[1-(phenylmethyl)-3-pyrrolidinyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI)
(CA INDEX NAME)




RN 612093-59-1 CAPLUS


CN Benzenesulfonamide, N-methyl-N-[1-(phenylmethyl)-3-pyrrolidinyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612093-60-4 CAPLUS
 CN Benzenesulfonamide, N-(6-methoxy-3-pyridinyl)-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612093-61-5 CAPLUS
 CN Benzenesulfonamide, N-[2-(2-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)



RN 612093-62-6 CAPLUS
 CN Benzenesulfonamide, N-2-pyridinyl-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612093-63-7 CAPLUS
 CN Benzenesulfonamide, N-(5-methyl-2-pyridinyl)-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612093-64-8 CAPLUS

CN Piperazine, 1-phenyl-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)






RN 612093-65-9 CAPLUS


CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 612093-66-0 CAPLUS


CN Piperazine, 1-(3,5-dichloro-4-pyridinyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)






RN 612093-70-6 CAPLUS

CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[(2,4-difluorophenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 612093-71-7 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)methyl]-4-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-72-8 CAPLUS


CN Piperazine, 1-[(3-chlorophenyl)methyl]-4-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-73-9 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)methyl]-4-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-
 (9CI) (CA INDEX NAME)




RN 612093-74-0 CAPLUS
 CN Piperazine, 1-[(2-bromophenyl)methyl]-4-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-
 (9CI) (CA INDEX NAME)




RN 612093-75-1 CAPLUS
 CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[[4-(trifluoromethyl)phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 612093-76-2 CAPLUS
 CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 612093-77-3 CAPLUS
 CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 612093-78-4 CAPLUS
 CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 612093-79-5 CAPLUS

CN Piperazine, 1-[(1,3-benzodioxol-5-ylmethyl)-4-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 612093-80-8 CAPLUS

CN Piperazine, 1-[(4-cyanophenyl)methyl]-4-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 612093-81-9 CAPLUS


CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(3-furanylmethyl)-(9CI) (CA INDEX NAME)




RN 612093-82-0 CAPLUS
 CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 612093-83-1 CAPLUS
 CN Piperazine, 1-[(5-chloro-2-thienyl)methyl]-4-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612093-84-2 CAPLUS
 CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)






RN 612093-85-3 CAPLUS
 CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 612093-86-4 CAPLUS
 CN 1H-1,4-Diazepine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[(4-fluorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)




RN 612093-87-5 CAPLUS
 CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)






RN 612093-91-1 CAPLUS

CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 612093-92-2 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612093-93-3 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612093-94-4 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612093-95-5 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[1-(2-thienylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612093-96-6 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-methyl-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612093-97-7 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[1-(phenylmethyl)-3-pyrrolidinyl]- (9CI)
(CA INDEX NAME)




RN 612093-98-8 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-methyl-N-[1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 612093-99-9 CAPLUS


CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 612094-00-5 CAPLUS
 CN Piperazine, 1-(phenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-01-6 CAPLUS
 CN Piperazine, 1-[(4-fluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-02-7 CAPLUS
 CN Piperazine, 1-[(3-fluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-03-8 CAPLUS
 CN Piperazine, 1-[(2,4-difluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-04-9 CAPLUS
 CN Piperazine, 1-[(4-chlorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-05-0 CAPLUS
 CN Piperazine, 1-[(3-chlorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-06-1 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-07-2 CAPLUS
 CN Piperazine, 1-[(2-bromophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-08-3 CAPLUS
 CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612094-09-4 CAPLUS
 CN Piperazine, 1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-10-7 CAPLUS
 CN Piperazine, 1-[(4-methoxyphenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME).



RN 612094-11-8 CAPLUS
 CN Piperazine, 1-[(3-methoxyphenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612094-12-9 CAPLUS
 CN Piperazine, 1-(1,3-benzodioxol-5-ylmethyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612094-13-0 CAPLUS

CN Piperazine, 1-[(4-cyanophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-14-1 CAPLUS

CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 612094-15-2 CAPLUS


CN Piperazine, 1-[(5-chloro-2-thienyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-16-3 CAPLUS
 CN Piperazine, 1-(4-pyridinylmethyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-17-4 CAPLUS
 CN Piperazine, 1-(1-phenylethyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 612094-18-5 CAPLUS
 CN 1H-1,4-Diazepine, 1-[(4-fluorophenyl)methyl]hexahydro-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-19-6 CAPLUS
 CN Piperazine, 1-(2-phenylethyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-20-9 CAPLUS

CN Piperazine, 1-(2-pyridinyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-21-0 CAPLUS

CN Benzenesulfonamide, N-[1-(phenylmethyl)-4-piperidinyl]-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-22-1 CAPLUS

CN Benzenesulfonamide, N-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-23-2 CAPLUS

CN Benzenesulfonamide, N-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-24-3 CAPLUS

CN Benzenesulfonamide, 4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[1-(2-thienylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612094-25-4 CAPLUS

CN Benzenesulfonamide, N-methyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-26-5 CAPLUS

CN Benzenesulfonamide, N-[1-(phenylmethyl)-3-pyrrolidinyl]-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI)
(CA INDEX NAME)




RN 612094-27-6 CAPLUS

CN Benzenesulfonamide, N-(6-methoxy-3-pyridinyl)-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-28-7 CAPLUS


CN Benzenesulfonamide, N-[2-(2-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-29-8 CAPLUS
 CN Benzenesulfonamide, N-2-pyridinyl-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-30-1 CAPLUS
 CN Piperazine, 1-(phenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 612094-31-2 CAPLUS
 CN Piperazine, 1-[(4-fluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-32-3 CAPLUS
 CN Piperazine, 1-[(3-fluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-33-4 CAPLUS

CN Piperazine, 1-[(2,4-difluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-35-6 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-36-7 CAPLUS


CN Piperazine, 1-[(3-chlorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-37-8 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612094-38-9 CAPLUS
 CN Piperazine, 1-[(2-bromophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612094-40-3 CAPLUS
 CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612094-41-4 CAPLUS
 CN Piperazine, 1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 612094-42-5 CAPLUS
 CN Piperazine, 1-[(4-methoxyphenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-43-6 CAPLUS
 CN Piperazine, 1-[(3-methoxyphenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-44-7 CAPLUS

CN Piperazine, 1-(1,3-benzodioxol-5-ylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-45-8 CAPLUS

CN Piperazine, 1-[(4-cyanophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-46-9 CAPLUS


CN Piperazine, 1-(3-furanylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-47-0 CAPLUS
 CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(2-thienylmethyl)- (9CI)
 (CA INDEX NAME)



RN 612094-48-1 CAPLUS
 CN Piperazine, 1-[(5-chloro-2-thienyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-49-2 CAPLUS
 CN Piperazine, 1-(4-pyridinylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612094-50-5 CAPLUS

CN 1H-1,4-Diazepine, 1-[(4-fluorophenyl)methyl]hexahydro-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-51-6 CAPLUS

CN Benzenesulfonamide, N-[2-[methyl(phenylmethyl)amino]ethyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-52-7 CAPLUS

CN Piperazine, 1-(2-pyridinyl)-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-53-8 CAPLUS

CN Benzenesulfonamide, N-[1-(phenylmethyl)-4-piperidinyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 612094-54-9 CAPLUS

CN Benzenesulfonamide, N-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 612094-55-0 CAPLUS

CN Benzenesulfonamide, N-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 612094-56-1 CAPLUS

CN Benzenesulfonamide, 4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[1-(2-thienylmethyl)-4-piperidinyl]- (9CI)
(CA INDEX NAME)




RN 612094-57-2 CAPLUS

CN Benzenesulfonamide, N-methyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-58-3 CAPLUS


CN Benzenesulfonamide, N-[2-(2-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-59-4 CAPLUS
 CN Piperazine, 1-(phenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-60-7 CAPLUS
 CN Piperazine, 1-[(4-fluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-61-8 CAPLUS
 CN Piperazine, 1-[(3-fluorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-62-9 CAPLUS
 CN Piperazine, 1-[(4-chlorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)



RN 612094-63-0 CAPLUS
 CN Piperazine, 1-[(3-chlorophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612094-64-1 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612094-65-2 CAPLUS

CN Piperazine, 1-[(2-bromophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
(CA INDEX NAME)




RN 612094-66-3 CAPLUS

CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612094-67-4 CAPLUS


CN Piperazine, 1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-68-5 CAPLUS
 CN Piperazine, 1-[(4-methoxyphenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)



RN 612094-69-6 CAPLUS
 CN Piperazine, 1-[(3-methoxyphenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612094-70-9 CAPLUS
 CN Piperazine, 1-(1,3-benzodioxol-5-ylmethyl)-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-71-0 CAPLUS

CN Piperazine, 1-[(4-cyanophenyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
(CA INDEX NAME)




RN 612094-72-1 CAPLUS

CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(2-thienylmethyl)- (9CI)
(CA INDEX NAME)




RN 612094-73-2 CAPLUS


CN Piperazine, 1-[(5-chloro-2-thienyl)methyl]-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
(CA INDEX NAME)




RN 612094-74-3 CAPLUS
 CN Piperazine, 1-(4-pyridinylmethyl)-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 612094-75-4 CAPLUS
 CN Piperazine, 1-(1-phenylethyl)-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-76-5 CAPLUS
 CN 1H-1,4-Diazepine, hexahydro-1-(phenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-77-6 CAPLUS
 CN 1H-1,4-Diazepine, 1-[(4-fluorophenyl)methyl]hexahydro-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-78-7 CAPLUS
 CN Piperazine, 1-(2-phenylethyl)-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 612094-79-8 CAPLUS
 CN 2,5-Diazabicyclo[2.2.1]heptane, 2-(phenylmethyl)-5-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-80-1 CAPLUS
 CN Benzenesulfonamide, N-[2-[methyl(phenylmethyl)amino]ethyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-81-2 CAPLUS

CN Benzenesulfonamide, N-[2-[(2-hydroxyethyl)(phenylmethyl)amino]ethyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-82-3 CAPLUS

CN Piperazine, 1-(2-pyridinyl)-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612094-83-4 CAPLUS

CN Benzenesulfonamide, N-[1-(phenylmethyl)-4-piperidinyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-84-5 CAPLUS

CN Benzenesulfonamide, N-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-85-6 CAPLUS

CN Benzenesulfonamide, N-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-86-7 CAPLUS

CN Benzenesulfonamide, 4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[1-(2-thienylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612094-87-8 CAPLUS

CN Benzenesulfonamide, N-methyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-88-9 CAPLUS

CN Benzenesulfonamide, N-[2-(2-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-89-0 CAPLUS

CN Piperazine, 1-[[4-(7-chloro-2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 612094-90-3 CAPLUS

CN Benzenesulfonamide, N-(2-pyridinylmethyl)-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-91-4 CAPLUS

CN Benzenesulfonamide, N-(3-pyridinylmethyl)-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-92-5 CAPLUS


CN Benzenesulfonamide, N-(4-pyridinylmethyl)-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-93-6 CAPLUS
 CN Benzenesulfonamide, N-[(6-methoxy-3-pyridinyl)methyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI)
 (CA INDEX NAME)




RN 612094-94-7 CAPLUS
 CN Benzenesulfonamide, N-[(3-chloro-4-pyridinyl)methyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)



RN 612094-95-8 CAPLUS
 CN Benzenesulfonamide, N-methyl-N-[2-(2-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI)
 (CA INDEX NAME)




RN 612094-96-9 CAPLUS
 CN Benzenesulfonamide, N-[2-(3-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-97-0 CAPLUS

CN Benzenesulfonamide, N-[2-(4-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-98-1 CAPLUS

CN Benzenesulfonamide, N-[2-(2-pyridinyloxy)ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612094-99-2 CAPLUS


CN Benzenesulfonamide, N-[2-[(6-methoxy-2-pyridinyl)oxy]ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-00-8 CAPLUS
 CN Benzenesulfonamide, N-[2-[(4-methyl-2-pyridinyl)oxy]ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI)
 (CA INDEX NAME)




RN 612095-01-9 CAPLUS
 CN Benzenesulfonamide, N-[2-[(5-chloro-2-pyridinyl)oxy]ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI)
 (CA INDEX NAME)




RN 612095-02-0 CAPLUS
 CN Benzenesulfonamide, 4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[2-[[5-(trifluoromethyl)-2-pyridinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 612095-03-1 CAPLUS
 CN Benzenesulfonamide, N-[2-(3-pyridinyloxy)ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-04-2 CAPLUS
 CN Benzenesulfonamide, N-[2-(pyrazinyloxy)ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)



RN 612095-05-3 CAPLUS
 CN Benzenesulfonamide, N-[2-(2-pyridinylthio)ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-06-4 CAPLUS
 CN Benzenesulfonamide, N-[2-(2-pyrimidinylthio)ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-07-5 CAPLUS

CN Benzenesulfonamide, N-(phenylmethyl)-N-[2-(2-pyridinyloxy)ethyl]-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-08-6 CAPLUS

CN Benzenesulfonamide, N-[2-[(6-methoxy-2-pyridinyl)oxy]ethyl]-N-(phenylmethyl)-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-09-7 CAPLUS

CN Benzenesulfonamide, N-[2-[(6-chloro-3-pyridinyl)oxy]ethyl]-N-(phenylmethyl)-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-10-0 CAPLUS

CN Piperidine, 4-(phenylmethyl)-1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612095-11-1 CAPLUS

CN Piperidine, 4-(3-methoxyphenyl)-1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 612095-12-2 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 612095-13-3 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 612095-14-4 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 612095-15-5 CAPLUS

CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 612095-16-6 CAPLUS


CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-methyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 612095-17-7 CAPLUS
 CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 612095-18-8 CAPLUS
 CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 612095-19-9 CAPLUS
 CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 612095-20-2 CAPLUS
 CN Benzenesulfonamide, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-(phenylmethyl)-N-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 612095-21-3 CAPLUS

CN Benzenesulfonamide, N-methyl-N-[2-(2-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI)
(CA INDEX NAME)




RN 612095-22-4 CAPLUS

CN Benzenesulfonamide, N-(2-pyridinylmethyl)-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-23-5 CAPLUS

CN Benzenesulfonamide, N-(3-pyridinylmethyl)-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-24-6 CAPLUS

CN Benzenesulfonamide, N-[(6-methoxy-3-pyridinyl)methyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 612095-25-7 CAPLUS

CN Benzenesulfonamide, N-methyl-N-[2-(2-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 612095-27-9 CAPLUS

CN Benzenesulfonamide, N-[2-(3-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 612095-28-0 CAPLUS


CN Benzenesulfonamide, N-[2-(4-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 612095-30-4 CAPLUS
 CN Benzenesulfonamide, N-[2-(2-pyridinyloxy)ethyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)



RN 612095-32-6 CAPLUS
 CN Benzenesulfonamide, N-(phenylmethyl)-N-[2-(2-pyridinyloxy)ethyl]-4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-33-7 CAPLUS
 CN Benzenesulfonamide, N-(2-pyridinylmethyl)-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-35-9 CAPLUS

CN Benzenesulfonamide, N-(3-pyridinylmethyl)-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-36-0 CAPLUS

CN Benzenesulfonamide, N-(4-pyridinylmethyl)-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-37-1 CAPLUS

CN Benzenesulfonamide, N-[(6-methoxy-3-pyridinyl)methyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-38-2 CAPLUS

CN Benzenesulfonamide, N-[(3-chloro-4-pyridinyl)methyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-39-3 CAPLUS

CN Benzenesulfonamide, N-methyl-N-[2-(2-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 612095-40-6 CAPLUS

CN Benzenesulfonamide, N-[2-(3-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 612095-41-7 CAPLUS


CN Benzenesulfonamide, N-[2-(4-pyridinyl)ethyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 612095-42-8 CAPLUS
 CN Benzenesulfonamide, N-[2-(2-pyridinyloxy)ethyl]-4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




IT 59119-44-7P 612095-43-9P 612095-44-0P
 612095-45-1P 612095-46-2P 612095-47-3P
 612095-48-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of new 4-(pyrrolopyrimidin-6-yl)benzenesulfonamides as A2A and/or A2B adenosine receptor selective antagonists)
 RN 59119-44-7 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)



RN 612095-43-9 CAPLUS
 CN Benzenesulfonyl chloride, 4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-44-0 CAPLUS
 CN Benzenesulfonyl chloride, 4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-45-1 CAPLUS

CN Benzenesulfonyl chloride, 4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-46-2 CAPLUS

CN Benzenesulfonyl chloride, 4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 612095-47-3 CAPLUS


CN Benzenesulfonyl chloride, 4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)



RN 612095-48-4 CAPLUS
 CN Benzenesulfonyl chloride, 4-(7-chloro-2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1, R2 = H, alkyl, haloalkyl, etc.; R3 = H, halo, NO2, etc.; R4, R5 = H, alkyl, (CH2)_nR6 (n = 0-4; R6 = 3-7 membered (non)aromatic (hetero)cyclyl, which is optionally bridged and/or fused to another 3-7 membered (non)aromatic (hetero)cyclyl), etc.] which are new potent and selective antagonists of A2A and/or A2B adenosine receptors, were prepared and formulated. E.g., a multi-step synthesis of I [R1, R2 = Me; R3 = H; NR4R5 = 4-benzylpiperazino] (starting from 1,3,6-trimethyl-5-nitro-1H-pyrimidine-2,4-dione and benzaldehyde) which showed IC₅₀ of 16 nM against A2B receptor binding, was given.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:128673 CAPLUS

DOCUMENT NUMBER: 139:69217

TITLE: Fast and highly efficient one-pot synthesis of 9-deazaxanthines

AUTHOR(S): Stefanachi, Angela; Leonetti, Francesco; Cappa, Anna; Carotti, Angelo

CORPORATE SOURCE: Dipartimento Farmaco-Chimico, University of Bari, Bari, I-70125, Italy

SOURCE: Tetrahedron Letters (2003), 44(10), 2121-2123
 CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:69217


IT 85102-47-2P 548943-22-2P 548943-27-7P
 548943-30-2P 548943-34-6P 548943-37-9P
 548943-40-4P 548943-45-9P 548943-48-2P
 548943-51-7P 548943-73-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(7-N-hydroxy-9-deazaxanthines; preparation of 9-deazaxanthines by one-pot heterocyclization of 5-nitro-1,3-dialkyl-6-styryl(furyl-, thienyl-vinyl)-uracils using SnCl₂ catalyst)


RN 85102-47-2 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-1,3-dimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 548943-22-2 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-6-(4-methylphenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-27-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-6-phenyl-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-30-2 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-6-(2-methylphenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-34-6 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(dimethylamino)phenyl]-5-hydroxy-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-37-9 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-6-(4-methoxyphenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)



RN 548943-40-4 CAPLUS
CN Acetamide, N-[4-(2,3,4,5-tetrahydro-5-hydroxy-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 548943-45-9 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(2-bromophenyl)-5-hydroxy-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-48-2 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(2-fluorophenyl)-5-hydroxy-

1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-51-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-6-[4-(1-methylethyl)phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)



RN 548943-73-3 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-acetylphenyl)-5-hydroxy-1,3-dipropyl- (9CI) (CA INDEX NAME)




IT 59119-46-9P 157119-69-2P 548943-76-6P
548943-84-6P 548943-87-9P 548943-90-4P
548943-93-7P 548943-96-0P 548944-00-9P
548944-03-2P 548944-16-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 9-deazaxanthines by one-pot heterocyclization of
5-nitro-1,3-dialkyl-6-styryl(furyl-, thienyl-vinyl)-uracils using SnCl₂
catalyst)

RN 59119-46-9 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 157119-69-2 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-phenyl-1,3-dipropyl- (9CI)
 (CA INDEX NAME)




RN 548943-76-6 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-methylphenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-84-6 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(2-methylphenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-87-9 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(dimethylamino)phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-90-4 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-methoxyphenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548943-93-7 CAPLUS
 CN Acetamide, N-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 548943-96-0 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(2-bromophenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 548944-00-9 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(2-fluorophenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)



RN 548944-03-2 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(1-methylethyl)phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)



RN 548944-16-7 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-acetylphenyl)-1,3-dipropyl- (9CI) (CA INDEX NAME)



AB SnCl₂ enables a direct, high-yield conversion of 5-nitro-1,3-dialkyl-6-styryl(furyl-, thienyl-vinyl)-uracils to 8-substituted-9-deazaxanthines under very mild exptl. conditions. The method has a general applicability and it is compatible with the reactivity of the most common organic functional groups. In slightly exptl. different conditions, it allows a high-yield and fast (<5 min) preparation of pure 7-N-hydroxy-9-deazaxanthines.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:5963 CAPLUS
 DOCUMENT NUMBER: 138:73267
 TITLE: Preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors
 INVENTOR(S): Vidal Juan, Bernat; Esteve Trias, Cristina; Segarra Matamoros, Victor; Ravina Rubira, Enrique; Fernandez Gonzalez, Franco; Loza Garcia, Maria Isabel; Sanz Carreras, Ferran
 PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain
 SOURCE: PCT Int. Appl., 168 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000694	A1	20030103	WO 2002-EP6727	20020618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2193839	A1	20031101	ES 2001-1452	20010622
ES 2193839	B1	20050216		
EP 1409489	A1	20040421	EP 2002-780834	20020618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534828	T	20041118	JP 2003-507097	20020618
US 2005070558	A1	20050331	US 2004-481728	20041019
PRIORITY APPLN. INFO.:			ES 2001-1452	A 20010622
			WO 2002-EP6727	W 20020618


OTHER SOURCE(S): MARPAT 138:73267

IT 480991-50-2P 480991-60-4P 480991-61-5P
 480991-63-7P 480991-68-2P 480993-28-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors)


RN 480991-50-2 CAPLUS

CN Benzeneacetic acid, 4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]-, ethyl ester (9CI)
 (CA INDEX NAME)



RN 480991-60-4 CAPLUS


CN Acetamide, N-(2-hydroxy-2-phenylethyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480991-61-5 CAPLUS


CN Acetamide, N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 480991-63-7 CAPLUS

CN Acetamide, N-[[3-hydroxy-1-(phenylmethyl)-3-piperidinyl]methyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-68-2 CAPLUS

CN Acetamide, N-(2-hydroxyphenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480993-28-0 CAPLUS

CN Benzenecarboximidamide, 4-fluoro-N-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



IT 480991-19-3P 480991-20-6P 480991-21-7P
 480991-22-8P 480991-23-9P 480991-24-0P
 480991-25-1P 480991-26-2P 480991-27-3P
 480991-28-4P 480991-29-5P 480991-30-8P
 480991-31-9P 480991-32-0P 480991-33-1P
 480991-34-2P 480991-35-3P 480991-36-4P
 480991-37-5P 480991-38-6P 480991-39-7P
 480991-40-0P 480991-41-1P 480991-42-2P
 480991-43-3P 480991-44-4P 480991-45-5P
 480991-46-6P 480991-47-7P 480991-48-8P
 480991-49-9P 480991-51-3P 480991-52-4P
 480991-53-5P 480991-54-6P 480991-55-7P
 480991-56-8P 480991-57-9P 480991-58-0P
 480991-59-1P 480991-62-6P 480991-64-8P
 480991-65-9P 480991-66-0P 480991-67-1P
 480991-69-3P 480991-70-6P 480991-71-7P
 480991-72-8P 480991-73-9P 480991-74-0P
 480991-75-1P 480991-76-2P 480991-77-3P
 480991-78-4P 480991-79-5P 480991-80-8P
 480991-81-9P 480991-82-0P 480991-83-1P
 480991-84-2P 480991-85-3P 480991-86-4P
 480991-87-5P 480991-88-6P 480991-89-7P
 480991-90-0P 480991-91-1P 480991-92-2P
 480991-93-3P 480991-94-4P 480991-95-5P
 480991-96-6P 480991-97-7P 480991-98-8P
 480991-99-9P 480992-00-5P 480992-01-6P
 480992-02-7P 480992-03-8P 480992-04-9P
 480992-05-0P 480992-06-1P 480992-07-2P
 480992-08-3P 480992-09-4P 480992-10-7P
 480992-11-8P 480992-12-9P 480992-13-0P
 480992-14-1P 480992-15-2P 480992-16-3P
 480992-17-4P 480992-18-5P 480992-19-6P
 480992-20-9P 480992-21-0P 480992-22-1P
 480992-23-2P 480992-24-3P 480992-25-4P
 480992-26-5P 480992-27-6P 480992-28-7P


480992-29-8P 480992-30-1P 480992-31-2P
 480992-32-3P 480992-33-4P 480992-34-5P
 480992-35-6P 480992-36-7P 480992-37-8P
 480992-38-9P 480992-39-0P 480992-40-3P
 480992-41-4P 480992-42-5P 480992-43-6P
 480992-44-7P 480992-45-8P 480992-46-9P
 480992-47-0P 480992-48-1P 480992-49-2P
 480992-50-5P 480992-51-6P 480992-52-7P
 480992-53-8P 480992-54-9P 480992-55-0P
 480992-56-1P 480992-57-2P 480992-58-3P
 480992-59-4P 480992-60-7P 480992-61-8P
 480992-62-9P 480992-63-0P 480992-64-1P
 480992-65-2P 480992-66-3P 480992-67-4P
 480992-68-5P 480992-69-6P 480992-70-9P
 480992-71-0P 480992-72-1P 480992-73-2P
 480992-74-3P 480992-75-4P 480992-76-5P
 480992-77-6P 480992-78-7P 480992-79-8P
 480992-80-1P 480992-81-2P 480992-82-3P
 480992-83-4P 480992-84-5P 480992-85-6P
 480992-86-7P 480992-87-8P 480992-88-9P
 480992-89-0P 480992-90-3P 480992-91-4P
 480992-92-5P 480992-93-6P 480992-94-7P
 480992-95-8P 480992-96-9P 480992-97-0P
 480992-98-1P 480992-99-2P 480993-00-8P
 480993-01-9P 480993-02-0P 480993-03-1P
 480993-04-2P 480993-05-3P 480993-06-4P
 480993-07-5P 480993-08-6P 480993-09-7P
 480993-10-0P 480993-11-1P 480993-12-2P
 480993-13-3P 480993-14-4P 480993-15-5P
 480993-16-6P 480993-17-7P 480993-18-8P
 480993-19-9P 480993-20-2P 480993-21-3P
 480993-22-4P 480993-23-5P 480993-24-6P
 480993-25-7P 480993-26-8P 480993-27-9P
 480993-29-1P 480993-30-4P 480993-31-5P
 480993-32-6P 480993-33-7P 480993-34-8P
 480993-35-9P 480993-36-0P 480993-37-1P
 480993-38-2P 480993-39-3P 480993-40-6P
 480993-41-7P 480993-42-8P 480993-43-9P
 480993-44-0P 480993-45-1P 480993-46-2P
 480993-47-3P 480993-48-4P 480993-49-5P
 480993-50-8P 480993-51-9P 480993-52-0P
 480993-53-1P 480993-54-2P 480993-55-3P
 480993-56-4P 480993-57-5P 480993-58-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor
 inhibitors)


RN 480991-19-3 CAPLUS

CN Acetamide, N-phenyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-
 pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-20-6 CAPLUS

CN Piperazine, 1-phenyl-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-21-7 CAPLUS

CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-22-8 CAPLUS


CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-23-9 CAPLUS
 CN Acetamide, N-(4-chlorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-24-0 CAPLUS
 CN Acetamide, 2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 480991-25-1 CAPLUS
 CN Acetamide, N-(4-cyanophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-26-2 CAPLUS
 CN Benzamide, 4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 480991-27-3 CAPLUS
 CN Piperazine, 1-pyrazinyl-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480991-28-4 CAPLUS
 CN Acetamide, N-(4-methoxyphenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-29-5 CAPLUS
 CN Acetamide, N-(4-methylphenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-30-8 CAPLUS

CN Acetamide, N-(4-acetylphenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-31-9 CAPLUS

CN Benzoic acid, 4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 480991-32-0 CAPLUS

CN Piperazine, 1-(2-chlorophenyl)-4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-33-1 CAPLUS

CN Acetamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-34-2 CAPLUS

CN 4-Piperidinecarbonitrile, 4-phenyl-1-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480991-35-3 CAPLUS


CN Piperazine, 1-(diphenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480991-36-4 CAPLUS

CN Acetamide, N-[(1R)-2-hydroxy-1-phenylethyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 480991-37-5 CAPLUS


CN Acetamide, N-[(1R)-2-chloro-1-phenylethyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 480991-38-6 CAPLUS

CN Acetamide, N-(4-benzoylphenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-39-7 CAPLUS

CN Acetamide, N-[4-(cyanomethyl)phenyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-40-0 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-41-1 CAPLUS

CN Acetamide, N-(4-hydroxyphenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-42-2 CAPLUS


CN Acetamide, N-[1,1'-biphenyl]-4-yl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-43-3 CAPLUS
 CN Acetamide, N-[4-(phenylmethoxy)phenyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-44-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 480991-45-5 CAPLUS
 CN Benzamide, N-[2-(4-methoxyphenyl)ethyl]-4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)






RN 480991-46-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-, phenyl ester
(9CI) (CA INDEX NAME)




RN 480991-47-7 CAPLUS

CN Acetamide, N-[4-[(1-pyrrolidinylsulfonyl)methyl]phenyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-
(9CI) (CA INDEX NAME)



RN 480991-48-8 CAPLUS


CN Piperidine, 4,4-diphenyl-1-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480991-49-9 CAPLUS


CN Piperidine, 4-(4-methoxyphenyl)-1-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-

dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-51-3 CAPLUS

CN Piperazine, 1-[(1-methyl-1H-benzimidazol-2-yl)methyl]-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-52-4 CAPLUS

CN Piperazine, 3,3-diphenyl-1-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-53-5 CAPLUS

CN Acetamide, N-[4-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)phenyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-54-6 CAPLUS

CN Benzenaminium, N,N,N-trimethyl-4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 480991-55-7 CAPLUS

CN Piperazine, 1-(3,5-dichloro-4-pyridinyl)-4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-56-8 CAPLUS


CN Piperazine, 1-(6-chloro-2-benzothiazolyl)-4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-57-9 CAPLUS
 CN Acetamide, N-[4-(acetylamino)phenyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480991-58-0 CAPLUS
 CN 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-2-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-59-1 CAPLUS
 CN Acetamide, N-(4-iodophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480991-62-6 CAPLUS
 CN Acetamide, 2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-3,3-


dimethyl-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 480991-64-8 CAPLUS

CN Acetamide, N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI)
(CA INDEX NAME)



RN 480991-65-9 CAPLUS


CN Acetamide, N-[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480991-66-0 CAPLUS


CN Acetamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 480991-67-1 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane, 2-(2-methylphenyl)-5-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480991-69-3 CAPLUS

CN Benzeneacetic acid, α -[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 480991-70-6 CAPLUS


CN Benzeneacetic acid, α -[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 480991-71-7 CAPLUS

CN Benzeneacetic acid, 4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 480991-72-8 CAPLUS

CN Acetamide, N-(2-aminoethyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-73-9 CAPLUS


CN Acetamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-74-0 CAPLUS
 CN Acetamide, N-phenyl-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-75-1 CAPLUS
 CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-76-2 CAPLUS
 CN Piperazine, 1-methyl-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-77-3 CAPLUS
 CN Morpholine, 4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-78-4 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480991-79-5 CAPLUS
 CN Acetamide, N-cyclopentyl-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-80-8 CAPLUS
 CN Acetamide, N-(4-acetylphenyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-81-9 CAPLUS

CN Acetamide, N-1H-benzimidazol-2-yl-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-82-0 CAPLUS

CN Acetamide, N-(4-cyanophenyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-83-1 CAPLUS

CN Quinoline, 1,2,3,4-tetrahydro-1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-84-2 CAPLUS

CN Acetamide, 2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-1,3,4-thiadiazol-2-yl- (9CI) (CA INDEX NAME)




RN 480991-85-3 CAPLUS

CN Piperazine, 1-phenyl-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-86-4 CAPLUS

CN Acetamide, N-(4-nitrophenyl)-2-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-87-5 CAPLUS


CN Piperazine, 1-(4-fluorophenyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-88-6 CAPLUS
 CN Piperazine, 1-(phenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-89-7 CAPLUS
 CN Piperazine, 1-(2-methoxyphenyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480991-90-0 CAPLUS
 CN Piperazine, 1-(4-methoxyphenyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-91-1 CAPLUS
 CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 480991-92-2 CAPLUS

CN Piperazine, 1-(2-pyridinyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-93-3 CAPLUS

CN Piperazine, 1-(2-pyrimidinyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480991-94-4 CAPLUS


CN Acetamide, N-methyl-N-(phenylmethyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-95-5 CAPLUS
 CN Acetamide, N-ethyl-N-(phenylmethyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-96-6 CAPLUS
 CN Acetamide, N-(2,3-dihydro-1H-inden-1-yl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-97-7 CAPLUS
 CN Acetamide, N-[(4-fluorophenyl)methyl]-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-98-8 CAPLUS
 CN Acetamide, N-(2-furanylmethyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480991-99-9 CAPLUS
 CN Acetamide, N-[(4-chlorophenyl)methyl]-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480992-00-5 CAPLUS
 CN Acetamide, N-(1-phenylethyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-01-6 CAPLUS
 CN Acetamide, N-[(3-methoxyphenyl)methyl]-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-02-7 CAPLUS

CN Acetamide, N-(phenylmethyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-03-8 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-(2-methylphenyl)-5-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-04-9 CAPLUS

CN Acetamide, 2-[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 480992-05-0 CAPLUS

CN Piperazine, 1-[[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480992-06-1 CAPLUS

CN Acetamide, N-(4-cyanophenyl)-2-[4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-07-2 CAPLUS

CN Acetamide, N-phenyl-2-[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-08-3 CAPLUS

CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-09-4 CAPLUS

CN Acetamide, N-[(4-chlorophenyl)methyl]-2-[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-10-7 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME).




RN 480992-11-8 CAPLUS

CN Piperazine, 1-phenyl-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-12-9 CAPLUS


CN Piperazine, 1-(4-fluorophenyl)-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-13-0 CAPLUS
 CN Benzoic acid, 4-[[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]-, ethyl ester (9CI)
 (CA INDEX NAME)



RN 480992-14-1 CAPLUS
 CN 4-Piperidinol, 4-phenyl-1-[[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-15-2 CAPLUS
 CN 4-Piperidinecarbonitrile, 4-phenyl-1-[[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-16-3 CAPLUS

CN Acetamide, N-[1,1'-biphenyl]-4-yl-2-[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-17-4 CAPLUS

CN Piperidine, 4,4-diphenyl-1-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-18-5 CAPLUS


CN Piperidine, 4-(4-methoxyphenyl)-1-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-19-6 CAPLUS
 CN Benzeneacetic acid, 4-[[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]-, ethyl ester (9CI)
 (CA INDEX NAME)




RN 480992-20-9 CAPLUS
 CN Piperazine, 3,3-diphenyl-1-[[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480992-21-0 CAPLUS
 CN Piperazine, 1-(6-chloro-2-benzothiazolyl)-4-[[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-22-1 CAPLUS
 CN 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-2-[[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-23-2 CAPLUS

CN Acetamide, N-(4-iodophenyl)-2-[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-24-3 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-(2-methylphenyl)-5-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-25-4 CAPLUS

CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-26-5 CAPLUS

CN Acetamide, N-phenyl-2-[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-27-6 CAPLUS

CN Acetamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-28-7 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-29-8 CAPLUS


CN Acetamide, N-(phenylmethyl)-2-[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-30-1 CAPLUS
 CN Acetamide, N-methyl-N-(phenylmethyl)-2-[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-31-2 CAPLUS
 CN Piperazine, 1-phenyl-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480992-32-3 CAPLUS
 CN Piperazine, 1-(phenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-33-4 CAPLUS
 CN 2,5-Diazabicyclo[2.2.1]heptane, 2-(2-methylphenyl)-5-[[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-34-5 CAPLUS

CN Acetamide, N-cyclopentyl-2-[4-[2,3,4,5-tetrahydro-1-(3-methoxypropyl)-3-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-35-6 CAPLUS

CN Acetamide, N-phenyl-2-[4-[2,3,4,5-tetrahydro-1-(3-methoxypropyl)-3-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-36-7 CAPLUS

CN Acetamide, N-phenyl-2-[4-[2,3,4,5-tetrahydro-1-methyl-3-(2-methylpropyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-37-8 CAPLUS

CN Piperazine, 1-phenyl-4-[[4-[2,3,4,5-tetrahydro-1-methyl-3-(2-methylpropyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-38-9 CAPLUS

CN Benzoic acid, 4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 480992-39-0 CAPLUS

CN Piperidine, 4-(4-methoxyphenyl)-1-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-40-3 CAPLUS

CN Piperazine, 1-(4-methoxyphenyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-41-4 CAPLUS

CN Acetamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-42-5 CAPLUS

CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-43-6 CAPLUS

CN Acetamide, N-phenyl-2-[4-[2,3,4,5-tetrahydro-1,3-bis(2-methoxyethyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-44-7 CAPLUS

CN Acetamide, N-(4-fluorophenyl)-2-[4-[2,3,4,5-tetrahydro-1,3-bis(2-methoxyethyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-45-8 CAPLUS


CN Acetamide, N-(4-bromophenyl)-2-[4-[2,3,4,5-tetrahydro-1,3-bis(2-methoxyethyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-46-9 CAPLUS
 CN Piperazine, 1-phenyl-4-[[4-[2,3,4,5-tetrahydro-1,3-bis(2-methoxyethyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480992-47-0 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-[2,3,4,5-tetrahydro-1,3-bis(2-methoxyethyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-48-1 CAPLUS
 CN Acetamide, 2-[4-[1,3-bis(cyclopropylmethyl)-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 480992-49-2 CAPLUS

CN Acetamide, 2-[4-[1,3-bis(cyclopropylmethyl)-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 480992-50-5 CAPLUS

CN Acetamide, 2-[4-[1,3-bis(cyclopropylmethyl)-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]-N-(4-bromophenyl)- (9CI) (CA INDEX NAME)




RN 480992-51-6 CAPLUS

CN Piperazine, 1-[[4-[1,3-bis(cyclopropylmethyl)-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480992-52-7 CAPLUS

CN Isoquinoline, 2-[[4-[1,3-bis(cyclopropylmethyl)-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 480992-53-8 CAPLUS

CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 480992-54-9 CAPLUS


CN Acetamide, 2-[4-(7-bromo-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 480992-55-0 CAPLUS
 CN Acetamide, 2-[4-(7-bromo-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 480992-56-1 CAPLUS
 CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 480992-57-2 CAPLUS
 CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 480992-58-3 CAPLUS

CN Acetamide, N-(4-bromophenyl)-2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-59-4 CAPLUS

CN Acetamide, N-(2-chlorophenyl)-2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-60-7 CAPLUS

CN Acetamide, N-(4-chlorophenyl)-2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-61-8 CAPLUS


CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 480992-62-9 CAPLUS
 CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-[(4-fluorophenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 480992-63-0 CAPLUS
 CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 480992-64-1 CAPLUS
 CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 480992-65-2 CAPLUS
 CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 480992-66-3 CAPLUS
 CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 480992-67-4 CAPLUS
 CN Acetamide, 2-[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 480992-68-5 CAPLUS
 CN Acetamide, N-(4-fluorophenyl)-2-[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-69-6 CAPLUS

CN Acetamide, N-[(4-chlorophenyl)methyl]-2-[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI)
(CA INDEX NAME)




RN 480992-70-9 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI)
(CA INDEX NAME)




RN 480992-71-0 CAPLUS

CN Piperazine, 1-[[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480992-72-1 CAPLUS

CN Acetamide, N-(4-cyanophenyl)-2-[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-73-2 CAPLUS

CN Acetamide, N-(4-bromophenyl)-2-[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-74-3 CAPLUS

CN Piperidine, 4-(4-methoxyphenyl)-1-[[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480992-75-4 CAPLUS

CN Piperazine, 1-(4-methoxyphenyl)-4-[[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI)
(CA INDEX NAME)




RN 480992-76-5 CAPLUS

CN Acetamide, 2-[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 480992-77-6 CAPLUS

CN Acetamide, N-(4-fluorophenyl)-2-[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-78-7 CAPLUS

CN Acetamide, N-[(4-chlorophenyl)methyl]-2-[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI)
(CA INDEX NAME)




RN 480992-79-8 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI)
(CA INDEX NAME)




RN 480992-80-1 CAPLUS

CN Piperazine, 1-[[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480992-81-2 CAPLUS

CN Acetamide, N-(4-cyanophenyl)-2-[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-82-3 CAPLUS

CN Acetamide, N-(4-bromophenyl)-2-[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-83-4 CAPLUS

CN Benzoic acid, 4-[[[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 480992-84-5 CAPLUS

CN Piperidine, 4-(4-methoxyphenyl)-1-[[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI)
(CA INDEX NAME)




RN 480992-85-6 CAPLUS

CN Piperazine, 1-(4-methoxyphenyl)-4-[[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI)
(CA INDEX NAME)




RN 480992-86-7 CAPLUS

CN Propanamide, N-phenyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-87-8 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-[1-oxo-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]propyl]- (9CI)
(CA INDEX NAME)




RN 480992-88-9 CAPLUS

CN Piperazine, 1-[1-oxo-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]propyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480992-89-0 CAPLUS


CN Propanamide, N-[(4-chlorophenyl)methyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-90-3 CAPLUS
 CN Propanamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480992-91-4 CAPLUS
 CN Propanamide, N-(4-methoxyphenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-92-5 CAPLUS
 CN Propanamide, N-phenyl-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-93-6 CAPLUS

CN Propanamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-94-7 CAPLUS

CN Propanamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-95-8 CAPLUS

CN Piperazine, 1-[1-oxo-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]propyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480992-96-9 CAPLUS


CN Isoquinoline, 1,2,3,4-tetrahydro-2-[1-oxo-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 480992-97-0 CAPLUS
 CN Butanamide, N-phenyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-98-1 CAPLUS
 CN Butanamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480992-99-2 CAPLUS
 CN Butanamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-00-8 CAPLUS
 CN Piperazine, 1-[1-oxo-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]butyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480993-01-9 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[1-oxo-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]butyl]- (9CI) (CA INDEX NAME)



RN 480993-02-0 CAPLUS
 CN Propanamide, 2-methyl-N-phenyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-03-1 CAPLUS
 CN Propanamide, N-(4-fluorophenyl)-2-methyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-04-2 CAPLUS

CN Propanamide, N-(4-bromophenyl)-2-methyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-05-3 CAPLUS

CN Piperazine, 1-[2-methyl-1-oxo-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]propyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480993-06-4 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-[2-methyl-1-oxo-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 480993-07-5 CAPLUS

CN Benzeneacetamide, N-phenyl- α -[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-08-6 CAPLUS

CN Benzeneacetamide, N-(4-fluorophenyl)- α -[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-09-7 CAPLUS


CN Piperazine, 1-phenyl-4-[phenyl[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-10-0 CAPLUS
 CN Benzenepropanamide, N-phenyl-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 480993-11-1 CAPLUS
 CN Benzenepropanamide, N-(4-fluorophenyl)-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME).




RN 480993-12-2 CAPLUS
 CN Piperazine, 1-[1-oxo-3-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]propyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480993-13-3 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[1-oxo-3-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]propyl]- (9CI) (CA INDEX NAME)




RN 480993-14-4 CAPLUS
 CN 2-Propenamide, N-phenyl-3-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 480993-15-5 CAPLUS
 CN Piperazine, 1-[1-oxo-3-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]-2-propenyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480993-16-6 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[1-oxo-3-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]-2-propenyl]- (9CI) (CA INDEX NAME)




RN 480993-17-7 CAPLUS
 CN Butanamide, N-phenyl-4-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-18-8 CAPLUS
 CN Butanamide, N-(4-fluorophenyl)-4-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480993-19-9 CAPLUS
 CN Piperazine, 1-[1-oxo-4-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]butyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 480993-20-2 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[1-oxo-4-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]butyl]- (9CI) (CA INDEX NAME)




RN 480993-21-3 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-(2-methylphenyl)-5-[1-oxo-4-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]butyl]- (9CI) (CA INDEX NAME)




RN 480993-22-4 CAPLUS

CN Benzamide, N-phenyl-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 480993-23-5 CAPLUS


CN Benzamide, N-(4-fluorophenyl)-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 480993-24-6 CAPLUS
 CN Benzamide, N-(4-bromophenyl)-4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 480993-25-7 CAPLUS
 CN Piperazine, 1-phenyl-4-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)benzoyl]- (9CI) (CA INDEX NAME)




RN 480993-26-8 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)benzoyl]- (9CI) (CA INDEX NAME)




RN 480993-27-9 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[(3-phenyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 480993-29-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 480993-30-4 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dipropyl-6-[4-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 480993-31-5 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(2-benzoxazolylmethoxy)phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 480993-32-6 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[(4,5-dihydro-5-phenyl-2-oxazolyl)methoxy]phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)



RN 480993-33-7 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[[4-methyl-5-phenyl-2-oxazolyl]methoxy]phenyl]-1,3-dipropyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 480993-34-8 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[[7-(phenylmethyl)-1-oxa-3,7-diazaspiro[4.5]dec-2-en-2-yl]methoxy]phenyl]-1,3-dipropyl-, (9CI) (CA INDEX NAME)




RN 480993-35-9 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dipropyl-6-[4-(2-quinolinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 480993-36-0 CAPLUS
 CN Acetamide, N-2-pyridinyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480993-37-1 CAPLUS
 CN Acetamide, N-(3-hydroxy-2-pyridinyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-38-2 CAPLUS
 CN Acetamide, N-(5-methyl-2-pyridinyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-39-3 CAPLUS

CN Acetamide, N-3-pyridinyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-40-6 CAPLUS

CN Acetamide, N-(5-methoxy-2-pyridinyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-41-7 CAPLUS

CN Acetamide, N-(4-pyridinylmethyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-42-8 CAPLUS


CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 480993-43-9 CAPLUS
 CN Piperazine, 1-(3-chlorophenyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-44-0 CAPLUS
 CN Acetamide, N-pyrazinyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-45-1 CAPLUS
 CN Acetamide, N-(2,6-dimethoxy-4-pyrimidinyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-46-2 CAPLUS
 CN 1H-Pyrazol-3-amine, 1-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480993-47-3 CAPLUS
 CN Piperazine, 1-(3-chlorophenyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-48-4 CAPLUS
 CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 480993-49-5 CAPLUS

CN Piperazine, 1-(4-bromophenyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)







RN 480993-50-8 CAPLUS

CN 4-Piperidinol, 4-phenyl-1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-51-9 CAPLUS


CN 4-Piperidinecarbonitrile, 4-phenyl-1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-55-3 CAPLUS
 CN Piperazine, 1-(5-chloro-2-benzothiazolyl)-4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI)
 (CA INDEX NAME)




RN 480993-56-4 CAPLUS
 CN 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-2-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI)
 (CA INDEX NAME)



RN 480993-57-5 CAPLUS
 CN Piperidine, 4-(4-fluorobenzoyl)-1-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 480993-58-6 CAPLUS
 CN Acetamide, N-(4-pyridinylmethyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




IT 480993-59-7P 480993-60-0P 480993-61-1P
 480993-62-2P 480993-63-3P 480993-64-4P
 480993-65-5P 480993-66-6P 480993-67-7P
 480993-68-8P 480993-69-9P 480993-70-2P
 480993-71-3P 480993-72-4P 480993-73-5P
 480993-74-6P 480993-75-7P 480993-76-8P
 480993-77-9P 480993-78-0P 480993-79-1P
 480993-80-4P 480993-81-5P 480993-82-6P
 480993-83-7P 480993-84-8P 480993-85-9P
 480993-86-0P 480993-87-1P 480993-88-2P
 480993-89-3P 480993-90-6P 480993-91-7P
 480993-92-8P 480993-93-9P 480993-94-0P
 480993-95-1P 480993-96-2P 480993-97-3P
 480993-98-4P 480993-99-5P 480994-00-1P
 480994-01-2P 480994-02-3P 480994-03-4P
 480994-04-5P 480994-05-6P 480994-06-7P
 480994-07-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor
 inhibitors)


RN 480993-59-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-
 dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-, ethyl ester (9CI)
 (CA INDEX NAME)




RN 480993-60-0 CAPLUS


CN Piperidine, 4-(2-methoxyphenyl)-1-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-
 dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA
 INDEX NAME)




RN 480993-61-1 CAPLUS
 CN Piperazine, 1-(3,5-dichloro-4-pyridinyl)-4-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-(9CI) (CA INDEX NAME)



RN 480993-62-2 CAPLUS
 CN Acetamide, N-(5-methoxy-2-pyridinyl)-2-[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-(9CI) (CA INDEX NAME)




RN 480993-63-3 CAPLUS
 CN Piperazine, 1-[[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]-4-[4-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)




RN 480993-64-4 CAPLUS

CN Morpholine, 4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-65-5 CAPLUS

CN Piperazine, 1-methyl-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-66-6 CAPLUS

CN Acetamide, N-(2-hydroxyethyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-67-7 CAPLUS

CN Piperazine, 1-(2-methoxyphenyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-68-8 CAPLUS

CN Piperazine, 1-(phenylmethyl)-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-69-9 CAPLUS

CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-70-2 CAPLUS

CN Acetamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480993-71-3 CAPLUS

CN Piperazine, 1-phenyl-4-[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-72-4 CAPLUS

CN Piperazine, 1-(4-fluorophenyl)-4-[[4-[2,3,4,5-tetrahydro-3-methyl-1-[3-(4-morpholinyl)propyl]-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-73-5 CAPLUS

CN Piperazine, 1-phenyl-4-[[4-[2,3,4,5-tetrahydro-3-methyl-1-[3-(4-morpholinyl)propyl]-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 480993-74-6 CAPLUS


CN Piperazine, 1-[[4-[2,3,4,5-tetrahydro-3-methyl-1-[3-(4-morpholinyl)propyl]-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]acetyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 480993-75-7 CAPLUS
 CN Carbamic acid, pyrazinyl-, [4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl)methyl ester (9CI) (CA INDEX NAME)



RN 480993-76-8 CAPLUS
 CN Carbamic acid, (2,6-dimethoxy-4-pyrimidinyl)-, [4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl)methyl ester (9CI) (CA INDEX NAME)




RN 480993-77-9 CAPLUS
 CN Carbamic acid, (4-pyridinylmethyl)-, [4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl)methyl ester (9CI) (CA INDEX NAME)




RN 480993-78-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(3-chlorophenyl)-, [4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-79-1 CAPLUS

CN Carbamic acid, 1H-pyrazol-3-yl-, [4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-80-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-(trifluoromethyl)phenyl]-, [4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-81-5 CAPLUS

CN Carbamic acid, 3-isoxazolyl-, [4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-82-6 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-83-7 CAPLUS


CN Carbamic acid, (phenylmethyl)-, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-84-8 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-[4-
 [[[(phenylamino) carbonyl]oxy]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 480993-85-9 CAPLUS
 CN Carbamic acid, 2-pyridinyl-, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-
 1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-86-0 CAPLUS
 CN Carbamic acid, (5-methyl-2-pyridinyl)-, [4-(2,3,4,5-tetrahydro-1,3-
 dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester
 (9CI) (CA INDEX NAME)




RN 480993-87-1 CAPLUS
 CN Carbamic acid, 2-thienyl-, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-88-2 CAPLUS
 CN Carbamic acid, 3-thienyl-, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 480993-89-3 CAPLUS
 CN Carbamic acid, 2-furanyl-, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-90-6 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-phenyl-, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-91-7 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 480993-92-8 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dipropyl-6-[4-[2-[(2-thienylamino)oxy]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 480993-93-9 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[2-[[4-bromophenyl)amino]oxy]ethoxy]phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)



RN 480993-94-0 CAPLUS


CN Benzamide, 2,6-difluoro-N-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl]amino]carbonyl]- (9CI) (CA

INDEX NAME)




RN 480993-95-1 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[(5-fluoro-2-benzoxazolyl)methoxy]phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 480993-96-2 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-[4-(2-quinolinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 480993-97-3 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-[4-[(3-phenyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 480993-98-4 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1-methyl-6-[4-[(3-phenyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl]- (9CI) (CA INDEX NAME)

1,2,4-oxadiazol-5-yl)methoxy]phenyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 480993-99-5 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)methoxy]phenyl]-1-methyl-3-propyl- (9CI) (CA INDEX NAME)




RN 480994-00-1 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[(5-chloro-2-benzoxazolyl)methoxy]phenyl]-1-methyl-3-propyl- (9CI) (CA INDEX NAME)




RN 480994-01-2 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl)methoxy]phenyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 480994-02-3 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-[4-[1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 480994-03-4 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[1-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]ethoxy]phenyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 480994-04-5 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-[4-[1-[3-(2-thienyl)-1,2,4-oxadiazol-5-yl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 480994-05-6 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-[4-[1-[3-[4-(methylthio)phenyl]-1,2,4-oxadiazol-5-yl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 480994-06-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[(4-bromophenyl)amino]methyl]phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)



RN 480994-07-8 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[(phenylamino)methyl]phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




IT 480994-09-0P 480994-10-3P 480994-12-5P
 480994-13-6P 480994-14-7P 480994-15-8P
 480994-16-9P 480994-17-0P 480994-18-1P
 480994-19-2P 480994-20-5P 480994-21-6P
 480994-22-7P 480994-23-8P 480994-24-9P
 480994-25-0P 480994-26-1P 480994-27-2P
 480994-28-3P 480994-29-4P 480994-30-7P
 480994-31-8P 480994-32-9P 480994-33-0P
 480994-34-1P 480994-35-2P 480994-36-3P
 480994-37-4P 480994-39-6P 480994-41-0P
 480994-42-1P 480994-44-3P 480994-46-5P
 480994-47-6P 480994-48-7P 480994-49-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors)


RN 480994-09-0 CAPLUS

CN Acetic acid, [4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-10-3 CAPLUS

CN Acetic acid, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 480994-12-5 CAPLUS

CN Acetic acid, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-13-6 CAPLUS

CN Acetic acid, [4-(1,3-diethyl-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-14-7 CAPLUS

CN Acetic acid, [4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-15-8 CAPLUS

CN Acetic acid, [4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-16-9 CAPLUS

CN Acetic acid, [4-[2,3,4,5-tetrahydro-1-(3-methoxypropyl)-3-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 480994-17-0 CAPLUS

CN Acetic acid, [4-[2,3,4,5-tetrahydro-1-methyl-3-(2-methylpropyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-18-1 CAPLUS

CN Acetic acid, [4-(2,3,4,5-tetrahydro-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-19-2 CAPLUS


CN Acetic acid, [4-[2,3,4,5-tetrahydro-1,3-bis(2-methoxyethyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-20-5 CAPLUS
 CN Acetic acid, [4-[1,3-bis(cyclopropylmethyl)-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-21-6 CAPLUS
 CN Acetic acid, [4-(7-chloro-2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-22-7 CAPLUS
 CN Acetic acid, [4-(7-bromo-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-23-8 CAPLUS
 CN Acetic acid, [4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-24-9 CAPLUS
 CN Acetic acid, [3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-25-0 CAPLUS
 CN Acetic acid, [3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 480994-26-1 CAPLUS
 CN Acetic acid, [2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethoxy-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-27-2 CAPLUS
 CN Propanoic acid, 2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-28-3 CAPLUS
 CN Propanoic acid, 2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480994-29-4 CAPLUS
 CN Butanoic acid, 2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-30-7 CAPLUS
 CN Propanoic acid, 2-methyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-31-8 CAPLUS

CN Benzenecetic acid, α -[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-32-9 CAPLUS

CN Benzenepropanoic acid, 4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 480994-33-0 CAPLUS

CN 2-Propenoic acid, 3-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 480994-34-1 CAPLUS

CN Benzenebutanoic acid, 4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 480994-35-2 CAPLUS

CN Benzoic acid, 4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 480994-36-3 CAPLUS

CN Acetic acid, [4-(2,3,4,5-tetrahydro-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 480994-37-4 CAPLUS

CN Acetic acid, [4-[2,3,4,5-tetrahydro-3-methyl-1-[3-(4-morpholinyl)propyl]-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 480994-39-6 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(hydroxymethyl)phenyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 480994-41-0 CAPLUS
 CN Benzoic acid, 4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 480994-42-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(hydroxymethyl)phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 480994-44-3 CAPLUS
 CN Acetamide, N-[(hydroxyamino)phenylmethylene]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480994-46-5 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(2-hydroxyethoxy)phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 480994-47-6 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[(methylsulfonyl)oxymethyl]phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 480994-48-7 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(azidomethyl)phenyl]-

1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 480994-49-8 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(aminomethyl)phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)



GI



I

AB The title compds. [I; R1, R2 = H, (CH₂)_nR₇, (un)substituted alkyl (wherein n = 0-4; R₇ = cycloalkyl, (un)substituted Ph, 3-7 membered (non)aromatic ring containing 1-4 heteroatoms and which is optionally fused to (hetero)aromatic ring); R₃ = H, halo, NO₂, etc.; R₄, R₅ = H, halo, alkyl, etc.; L₁ = a direct bond, O, S, etc.; R₆ = CONR₁₀R₁₁, SO₂NR₁₀R₁₁, ON:CR₁₂R₁₃, aryl, etc.; R₁₀, R₁₁ = H, alkyl, cycloalkyl, etc.; R₁₂, R₁₃ = defined as R₁₀ and R₁₁, except that either or both of R₁₂ and R₁₃ can be an amino, alkylamino or dialkylamino] which have therapeutic potential as A₂ adenosine receptor inhibitors (biol. data given), were prepared and formulated. Thus, coupling {4-[2-(5-nitro-2,6-dioxo-1,3-dipropyl-1,2,3,6-tetrahydropyrimidin-4-yl)vinyl]phenoxy}acetic acid (preparation given) with aniline (yield 42%) followed by reductive cyclization of the resulting intermediate mediated by triethylphosphite (46%) afforded I [R₁, R₂ = Pr; R₃-R₅ = H; L₁ = OCH₂; R₆ = CONHPh].

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:415043 CAPLUS


DOCUMENT NUMBER: 137:294926

TITLE: A facile synthesis of pyrrolo[3,2-d]pyrimidines from


6-azidouracils and ylide phosphoranes
 AUTHOR(S): Abdou, Wafaa M.; Fahmy, Amin F. M.; Kamel, Azza A.
 CORPORATE SOURCE: National Research Centre, Cairo, Egypt
 SOURCE: Heteroatom Chemistry (2002), 13(4), 357-365
 CODEN: HETCE8; ISSN: 1042-7163
 PUBLISHER: John Wiley & Sons, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:294926
 IT 34771-39-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (facile synthesis of pyrrolo[3,2-d]pyrimidines from 6-azidouracils and
 ylide phosphoranes)
 RN 34771-39-6 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-phenyl- (9CI) (CA INDEX
 NAME)



IT 59119-44-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (facile synthesis of pyrrolo[3,2-d]pyrimidines from 6-azidouracils and
 ylide phosphoranes)
 RN 59119-44-7 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI)
 (CA INDEX NAME)



GI



AB A series of the title compds., 9-deazaxanthines, was regioselectively prepared in reasonable yields as major products from the reactions of 6-azidouracils I (R = H, Me) with stabilized ester or keto ylide

phosphoranes and a moderated phosphorus ylide, instead of the expected triazoles. Side products were also observed wherein pyrimido[5,4-g]pteridine-2,4,5,7-tetrone and other fused ring systems or acyclic-substituted uracil derivs. were isolated. A comparative study on the reactivity of I (R = H) in analogy to I (R = Me) toward phosphoranes is also described.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:123011 CAPLUS

DOCUMENT NUMBER: 136:183827

TITLE: Preparation of pyrrolotriazolopyrimidinones as inhibitors of phosphodiesterase V.

INVENTOR(S): Vidal Juan, Bernat; Esteve Trias, Cristina; Gracia Ferrer, Jordi; Prieto Soto, Jose Manuel

PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012246	A1	20020214	WO 2001-EP8904	20010801
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2417784	A1	20020214	CA 2001-2417784	20010801
AU 2001089782	A5	20020218	AU 2001-89782	20010801
EP 1307458	A1	20030507	EP 2001-969562	20010801
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004505980	T	20040226	JP 2002-518221	20010801
US 2004019034	A1	20040129	US 2003-343934	20030815
US 7060824	B2	20060613		

PRIORITY APPLN. INFO.: ES 2000-2039 A 20000809
WO 2001-EP8904 W 20010801

OTHER SOURCE(S): MARPAT 136:183827


IT 398479-71-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrrolotriazolopyrimidinones as inhibitors of phosphodiesterase V)

RN 398479-71-5 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(2-ethoxyphenyl)-1-propyl-(9CI) (CA INDEX NAME)



GI



I

AB Title compds. [I; XCY = NHC:CR6, R6C:CNH; R1-R3 = H, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, aminoalkyl, carboxyalkyl, alkoxy-carbonylalkyl, acylamino, carbamoylalkyl, alkylcarbamoylalkyl, (CH2)nR7; R4, R5 = H, amidino, (substituted) alkyl, alkenyl, alkynyl; or R4 = H, alkyl; R5 = (CH2)nR7; n = 0-4; R7 = (substituted) cycloalkyl, Ph, heterocyclyl; R4R5N = 3-7 membered (substituted) ring comprising 1-4 heteroatoms selected from N, O, S; R6 = H, halo, NO2, alkylcarbonyl, (substituted) alkyl], were prepared. Thus, 4-ethoxy-3-[5-oxo-6-propyl-6,9-dihydro-5H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-c]pyrimidin-8-yl]benzenesulfonyl chloride (preparation given), 1-ethylpiperazine, polymer-bound morpholine were stirred overnight in CH2Cl2 to give 8-[2-ethoxy-5-(4-ethylpiperazine-1-sulfonyl)phenyl]-6-propyl-6,9-dihydro-5H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-c]pyrimidine-5-one. Tested I inhibited phosphodiesterase V with IC50 = 0.099-0.3 nM.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:116697 CAPLUS

DOCUMENT NUMBER: 136:309794

TITLE: 1,8-Disubstituted Xanthine Derivatives: Synthesis of Potent A2B-Selective Adenosine Receptor Antagonists

AUTHOR(S): Hayallah, Alaa M.; Sandoval-Ramirez, Jesus; Reith, Ulrike; Schobert, Ulrike; Preiss, Birgit; Schumacher, Britta; Daly, John W.; Mueller, Christa E.

CORPORATE SOURCE: Pharmaceutical Institute Poppelsdorf, University of Bonn, Bonn, Germany

SOURCE: Journal of Medicinal Chemistry (2002), 45(7), 1500-1510

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 136:309794

IT 157119-66-9 157119-68-1


RL: PAC (Pharmacological activity); BIOL (Biological study)

(preparation, human, rat, or sheep adenosine receptor affinity and A2B-selective affinity, and structure-activity relationship of xanthine and deazaxanthine derivs.)

RN 157119-66-9 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 3-methyl-6-phenyl- (9CI)
(CA INDEX NAME)



RN 157119-68-1 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-phenyl-3-propyl- (9CI)
(CA INDEX NAME)



AB 3-Unsubstituted xanthine derivs. bearing a cyclopentyl or a Ph residue in the 8-position were synthesized and developed as A2B adenosine receptor antagonists. Compds. bearing polar substituents were prepared to obtain water-soluble derivs. 1-Alkyl-8-phenylxanthine derivs. were found to exhibit high affinity for A2B adenosine receptors (ARs). 1,8-Disubstituted xanthine derivs. were equipotent to or more potent than 1,3,8-trisubstituted xanthines at A2B ARs, but generally less potent at A1 and A2A, and much less potent at A3 ARs. Thus, the new compds. exhibited increased A2B selectivity vs. all other AR subtypes. 9-Deazaxanthines (pyrrolo[2,3-d]pyrimidindiones) appeared to be less potent at A2B ARs than the corresponding xanthine derivs. 1-Propyl-8-p-sulfophenylxanthine (I) was the most selective compound of the present series, exhibiting a K_i value of 53 nM at human A2B ARs and showing greater than 180-fold selectivity vs. human A1 ARs. Compound I was also highly selective vs. rat A1 ARs (41-fold) and vs. the other human AR subtypes (A2A > 400-fold and A3 > 180-fold). The compound is highly water-soluble due to its sulfonate function. 1-Butyl-8-p-carboxyphenylxanthine, another polar analog bearing a carboxylate function, exhibited a K_i value of 24 nM for A2B ARs, 49-fold selectivity vs. human and 20-fold selectivity vs. rat A1 ARs, and greater than 150-fold selectivity vs. human A2A and A3 ARs. 8-[4-[(2-Hydroxyethylamino)-2-oxoethoxy]phenyl]-1-propylxanthine (II) and 1-butyl-8-[4-[(4-benzylpiperazino)-2-oxoethoxy]phenyl]xanthine (III) were among the most potent A2B antagonists showing K_i values at A2B ARs of 1 nM, 57-fold for II and 94-fold for III selectivity vs. human A1, ca. 30-fold selectivity vs. rat A1, and greater than 400-fold selectivity vs. human A2A and A3 ARs. The new potent, selective, water-soluble A2B antagonists may be useful research tools for investigating A2B receptor function.

REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:904177 CAPLUS
DOCUMENT NUMBER: 136:37621
TITLE: Preparation of 6-phenylpyrrolopyrimidinedione

INVENTOR(S): derivatives
 Vidal Juan, Bernat; Gracia Ferrer, Jordi; Prieto Soto,
 Jose Manuel; Vega Noverola, Armando
 PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094350	A1	20011213	WO 2001-EP6306	20010601
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2411013	A1	20011213	CA 2001-2411013	20010601
EP 1286997	A1	20030305	EP 2001-960264	20010601
EP 1286997	B1	20040818		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003535864	T	20031202	JP 2002-501899	20010601
AT 273980	T	20040915	AT 2001-960264	20010601
ES 2222389	T3	20050201	ES 2001-1960264	20010601
US 2003232838	A1	20031218	US 2002-313922	20021206
US 6943253	B2	20050913		
PRIORITY APPLN. INFO.:			ES 2000-1436	A 20000607
			WO 2001-EP6306	W 20010601

OTHER SOURCE(S): MARPAT 136:37621
 IT 378793-92-1P 378793-93-2P 378793-94-3P
 378793-95-4P 378793-96-5P 378793-97-6P
 378793-98-7P 378793-99-8P 378794-00-4P
 378794-01-5P 378794-02-6P 378794-03-7P
 378794-04-8P 378794-05-9P 378794-06-0P
 378794-07-1P 378794-08-2P 378794-09-3P
 378794-10-6P 378794-12-8P 378794-13-9P
 378794-14-0P 378794-15-1P 378794-16-2P
 378794-17-3P 378794-18-4P 378794-19-5P
 378794-20-8P 378794-21-9P 378794-22-0P
 378794-23-1P 378794-24-2P 378794-25-3P
 378794-26-4P 378794-27-5P 378794-28-6P
 378794-29-7P 378794-30-0P 378794-31-1P
 378794-32-2P 378794-33-3P 378794-34-4P
 378794-35-5P 378794-36-6P 378794-37-7P
 378794-38-8P 378794-39-9P 378794-40-2P
 378794-41-3P 378794-42-4P 378794-43-5P
 378794-44-6P 378794-45-7P 378794-46-8P
 378794-47-9P 378794-48-0P 378794-49-1P
 378794-50-4P 378794-51-5P 378794-52-6P
 378794-53-7P 378794-54-8P 378794-55-9P
 378794-56-0P 378794-57-1P 378794-58-2P
 378794-59-3P 378794-61-7P 378794-62-8P
 378794-63-9P 378794-64-0P 378794-65-1P
 378794-66-2P 378794-67-3P 378794-68-4P
 378794-69-5P 378794-70-8P 378794-71-9P
 378794-72-0P 378794-73-1P 378794-74-2P

378794-75-3P 378794-76-4P 378794-77-5P


378794-78-6P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-phenylpyrrolopyrimidinedione derivs. as cyclic GMP specific phosphodiesterase (PDE 5) inhibitors)


RN 378793-92-1 CAPLUS

CN Piperazine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 378793-93-2 CAPLUS

CN Piperazine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378793-94-3 CAPLUS

CN Morpholine, 4-[[4-ethoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378793-95-4 CAPLUS


CN Benzenesulfonamide, N-[2-(dimethylamino)ethyl]-4-ethoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378793-96-5 CAPLUS
 CN Piperazine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 378793-97-6 CAPLUS
 CN 1H-1,4-Diazepine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 378793-98-7 CAPLUS
 CN Benzenesulfonamide, 4-ethoxy-N-[2-(1-piperidinyl)ethyl]-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378793-99-8 CAPLUS

CN Benzenesulfonamide, 4-ethoxy-N-[2-(4-morpholinyl)ethyl]-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 378794-00-4 CAPLUS

CN 1-Piperazineethanol, 4-[[4-ethoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 378794-01-5 CAPLUS

CN Benzenesulfonamide, 4-ethoxy-N-[3-(4-morpholinyl)propyl]-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-(9CI) (CA INDEX NAME)




RN 378794-02-6 CAPLUS


CN 1-Piperazinepropanol, 4-[[4-ethoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 378794-03-7 CAPLUS
 CN Piperazine, 1-methyl-4-[[[4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 378794-04-8 CAPLUS
 CN Piperazine, 1-ethyl-4-[[[4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-05-9 CAPLUS
 CN 1-Piperazineethanol, 4-[[[4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 378794-06-0 CAPLUS
 CN Piperazine, 1-[[[4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-07-1 CAPLUS
 CN Morpholine, 4-[[4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-08-2 CAPLUS
 CN Benzenesulfonamide, N-[2-(dimethylamino)ethyl]-4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378794-09-3 CAPLUS
 CN Benzenesulfonamide, N,N-bis(2-hydroxyethyl)-4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378794-10-6 CAPLUS
 CN 1H-1,4-Diazepine, hexahydro-1-methyl-4-[[4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-12-8 CAPLUS
 CN Benzenesulfonamide, N-(4-methyl-1-piperazinyl)-4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378794-13-9 CAPLUS
 CN Benzenesulfonamide, 4-propoxy-N-[2-(2-pyridinyl)ethyl]-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)



RN 378794-14-0 CAPLUS
 CN Benzenesulfonamide, N-[2-(1-piperidiny)ethyl]-4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378794-15-1 CAPLUS
 CN Benzenesulfonamide, N-[2-(4-morpholinyl)ethyl]-4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378794-16-2 CAPLUS

CN Benzenesulfonamide, N-[3-(4-morpholinyl)propyl]-4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378794-17-3 CAPLUS

CN 1-Piperazinepropanol, 4-[[4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 378794-18-4 CAPLUS


CN Piperazine, 1-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 378794-19-5 CAPLUS


CN Piperazine, 1-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI)

(CA INDEX NAME)




RN 378794-20-8 CAPLUS

CN Piperazine, 1-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl- (9CI)
(CA INDEX NAME)




RN 378794-21-9 CAPLUS

CN 1-Piperazineethanol, 4-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]- (9CI)
(CA INDEX NAME)




RN 378794-22-0 CAPLUS

CN Benzenesulfonamide, 3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[2-(dimethylamino)ethyl]-4-ethoxy- (9CI) (CA INDEX NAME)




RN 378794-23-1 CAPLUS

CN 1H-1,4-Diazepine, 1-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 378794-24-2 CAPLUS

CN Benzenesulfonamide, 3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 378794-25-3 CAPLUS

CN Piperazine, 1-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 378794-26-4 CAPLUS


CN Piperazine, 1-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxyphenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 378794-27-5 CAPLUS
 CN 1-Piperazineethanol, 4-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxyphenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)




RN 378794-28-6 CAPLUS
 CN Morpholine, 4-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 378794-29-7 CAPLUS
 CN Piperazine, 1-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI)
 (CA INDEX NAME)




RN 378794-30-0 CAPLUS
 CN 1-Piperazinecarboxaldehyde, 4-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-31-1 CAPLUS

CN Piperazine, 1-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl- (9CI)
(CA INDEX NAME)




RN 378794-32-2 CAPLUS

CN 1H-1,4-Diazepine, 1-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 378794-33-3 CAPLUS


CN Benzenesulfonamide, 3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy-N-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 378794-34-4 CAPLUS


CN Benzenesulfonamide, 3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy-N-[2-(2-pyridinyl)ethyl]-

(9CI) (CA INDEX NAME)




RN 378794-35-5 CAPLUS

CN Benzenesulfonamide, 3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 378794-36-6 CAPLUS

CN 1-Piperazineethanol, 4-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 378794-37-7 CAPLUS


CN Benzenesulfonamide, 3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 378794-38-8 CAPLUS


CN Benzenesulfonamide, 3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-

propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 378794-39-9 CAPLUS

CN 1-Piperazinepropanol, 4-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-40-2 CAPLUS

CN Piperazine, 1-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 378794-41-3 CAPLUS

CN Morpholine, 4-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-42-4 CAPLUS

CN Piperazine, 1-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxyphenyl]sulfonyl]-4-methyl- (9CI)
(CA INDEX NAME)




RN 378794-43-5 CAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-44-6 CAPLUS

CN Piperazine, 1-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxyphenyl]sulfonyl]-4-ethyl- (9CI)
(CA INDEX NAME)




RN 378794-45-7 CAPLUS

CN 1H-1,4-Diazepine, 1-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxyphenyl]sulfonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 378794-46-8 CAPLUS

CN Benzenesulfonamide, 3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[2-(4-morpholinyl)ethyl]-4-propoxy- (9CI) (CA INDEX NAME)




RN 378794-47-9 CAPLUS

CN 1-Piperazineethanol, 4-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-48-0 CAPLUS

CN Benzenesulfonamide, 3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-[3-(4-morpholinyl)propyl]-4-propoxy- (9CI) (CA INDEX NAME)




RN 378794-49-1 CAPLUS


CN 1-Piperazinepropanol, 4-[[3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-50-4 CAPLUS
 CN Piperazine, 1-[[3-[7-chloro-2,3,4,5-tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 378794-51-5 CAPLUS
 CN Piperazine, 1-[[3-[7-chloro-2,3,4,5-tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]-4-ethoxyphenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 378794-52-6 CAPLUS
 CN 1-Piperazineethanol, 4-[[3-[7-chloro-2,3,4,5-tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-53-7 CAPLUS
 CN Piperazine, 1-[[3-[7-chloro-2,3,4,5-tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-54-8 CAPLUS

CN Piperazine, 1-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 378794-55-9 CAPLUS

CN Benzenesulfonamide, 3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 378794-56-0 CAPLUS

CN 1-Piperazinepropanol, 4-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-57-1 CAPLUS

CN Benzenesulfonamide, 3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy-N-[2-(2-pyridinyl)ethyl]-
(9CI) (CA INDEX NAME)




RN 378794-58-2 CAPLUS

RN 378794-36-2 CAPLOS
 CN Piperazine, 1-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-
 1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]-4-(2-
 ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 378794-59-3 CAPLUS

RN	378794-59-5	CALBES
CN	Piperazine, 1-[[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl- 1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]-4-(2-propenyl)- (9CI)	(CA INDEX NAME)



RN 378794-61-7 CAPLUS


CN Piperazine, 1-[[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-
 1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]-4-(1-
 methylethyl)- (9CI) (CA INDEX NAME)



RN 378794-62-8 CAPLUS

CN Pyrrolo[1,2-a]pyrazine, 2-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]octahydro-, (8aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378794-63-9 CAPLUS

CN Pyrrolo[1,2-a]pyrazine, 2-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]octahydro-, (8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378794-64-0 CAPLUS

CN Pyrrolo[1,2-a]pyrazine, 2-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]octahydro-3-methyl-, (3R,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 378794-65-1 CAPLUS

CN Pyrrolo[1,2-a]pyrazin-7-ol, 2-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]octahydro-, (7R,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 378794-66-2 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[[3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxyphenyl]sulfonyl]-5-methyl-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 378794-67-3 CAPLUS

CN Piperazine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 378794-68-4 CAPLUS

CN 3-Azetidinamine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 378794-69-5 CAPLUS

CN 1H-1,4-Diazepine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 378794-70-8 CAPLUS

CN Piperazine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 378794-71-9 CAPLUS

CN Piperazine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 378794-72-0 CAPLUS

CN Piperazine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(1-methylethyl)-
(9CI) (CA INDEX NAME)




RN 378794-73-1 CAPLUS

CN 1-Piperazineethanol, 4-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI)
(CA INDEX NAME)




RN 378794-74-2 CAPLUS

CN Piperazine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-4-(2-methoxyethyl)-
(9CI) (CA INDEX NAME)




RN 378794-75-3 CAPLUS

CN Piperazine, 1-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 378794-76-4 CAPLUS

CN Benzenesulfonamide, 4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-N-(2,2,6,6-tetramethyl-4-piperidyl)- (9CI) (CA INDEX NAME)



RN 378794-77-5 CAPLUS


CN 1H-1,4-Diazepine-1-ethanol, 4-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]hexahydro- (9CI) (CA INDEX NAME)



RN 378794-78-6 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[[4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]sulfonyl]-5-methyl-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 378794-90-2P, 6-(2-Ethoxyphenyl)-3-methyl-1-propyl-1,5-dihydropyrrolo[3,2-d]pyrimidine-2,4-dione 378794-92-4P
378794-93-5P 378794-94-6P 378794-95-7P
378794-96-8P 378794-97-9P 378794-98-0P
378794-99-1P 378795-00-7P 378795-01-8P
378795-07-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 6-phenylpyrrolopyrimidinedione derivs. as cyclic GMP specific phosphodiesterase (PDE 5) inhibitors)


RN 378794-90-2 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(2-ethoxyphenyl)-3-methyl-1-propyl- (9CI) (CA INDEX NAME)




RN 378794-92-4 CAPLUS

CN Benzenesulfonyl chloride, 4-ethoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378794-93-5 CAPLUS

CN Benzenesulfonyl chloride, 3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy- (9CI) (CA INDEX NAME)




RN 378794-94-6 CAPLUS


CN Benzenesulfonyl chloride, 3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy- (9CI) (CA INDEX NAME)




RN 378794-95-7 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 3-methyl-6-(2-propoxyphenyl)-1-propyl- (9CI) (CA INDEX NAME)




RN 378794-96-8 CAPLUS
 CN Benzenesulfonyl chloride, 4-propoxy-3-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378794-97-9 CAPLUS
 CN Benzenesulfonyl chloride, 3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxy- (9CI) (CA INDEX NAME)




RN 378794-98-0 CAPLUS
 CN Benzenesulfonyl chloride, 3-(7-bromo-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-propoxy- (9CI) (CA INDEX NAME)




RN 378794-99-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(2-ethoxyphenyl)-3-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 378795-00-7 CAPLUS
 CN Benzenesulfonyl chloride, 3-[7-chloro-2,3,4,5-tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]-4-ethoxy- (9CI) (CA INDEX NAME)




RN 378795-01-8 CAPLUS
 CN Benzenesulfonyl chloride, 4-ethoxy-3-(2,3,4,5-tetrahydro-7-iodo-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 378795-07-4 CAPLUS
 CN Benzenesulfonamide, 3-(7-chloro-2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-

propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-4-ethoxy-N-[2-
[methyl (phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



GI



I

AB 6-Phenylpyrrolopyrimidine derivs. I [-X-C-Y- represents NHC:CR6 or -X-C-Y- represents CR6:CNH], useful as selective cyclic GMP specific phosphodiesterase (PDE 5) inhibitors, were prepared E.g., I [R1 = Me; R2 = Pr; R3 = Et; Y = CH:; X = NH; NR4R5 = 4-methylpiperazinyl] was prepared
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:727122 CAPLUS

DOCUMENT NUMBER: 134:50982

TITLE: Structure-Activity Relationships of a Series of

Pyrrolo[3,2-d]pyrimidine Derivatives and Related

Compounds as Neuropeptide Y5 Receptor Antagonists

AUTHOR(S): Norman, Mark H.; Chen, Ning; Chen, Zhidong; Fotsch,

Christopher; Hale, Clarence; Han, Nianhe; Hurt, Ray;

Jenkins, Tracy; Kincaid, John; Liu, Longbin; Lu,

Yuelie; Moreno, Ofir; Santora, Vincent J.; Sonnenberg,

Jennifer D.; Karbon, Willam

CORPORATE SOURCE: Departments of Small Molecule Drug Discovery and

Neuroscience, Amgen Inc., Thousand Oaks, CA,

91320-1789, USA

SOURCE: Journal of Medicinal Chemistry (2000), 43(22),

4288-4312

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:50982

IT 34771-39-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(structure-activity relationships of a series of pyrrolo[d]pyrimidine


derivs. and related compds. as neuropeptide Y5 receptor antagonists in relation to obesity treatment)

RN 34771-39-6 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-phenyl- (9CI) (CA INDEX NAME)



GI



I

AB Neuropeptide Y (NPY) has been shown to play an important role in the regulation of food intake and energy balance. Pharmacol. data suggests that the Y5 receptor subtype contributes to the effects of NPY on appetite, and therefore a Y5 antagonist might be a useful therapeutic agent for the treatment of obesity. In attempts to identify potential Y5 antagonists, a series of pyrrolo[3,2-d]pyrimidine derivs. was prepared and evaluated for their ability to bind to Y5 receptors in vitro. The authors report here the synthesis and initial structure-activity relation investigations for this class of compds. The target compds. were prepared by a variety of synthetic routes designed to modify both the substitution and the heterocyclic core of the pyrrolo[3,2-d]pyrimidine lead compound (I). In addition to identifying several potent Y5 antagonists for evaluation as potential antiobesity agents, a pharmacophore model for the human Y5 receptor is presented.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:784100 CAPLUS

DOCUMENT NUMBER: 132:12326

TITLE: Preparation of 8-phenylxanthine derivatives and their use as phosphodiesterase 5 inhibitors

INVENTOR(S): Vega Noverola, Armando; Gracia Ferrer, Jordi; Feixas Gras, Joan; Prieto Soto, Jose Manuel

PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962905	A1	19991209	WO 1999-EP3644	19990526
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9945011	A	19991220	AU 1999-45011	19990526
PRIORITY APPLN. INFO.:			ES 1998-1152	A 19980603
			WO 1999-EP3644	W 19990526


OTHER SOURCE(S): MARPAT 132:12326

IT 251473-42-4P 251473-43-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 8-phenylxanthines and their use as phosphodiesterase 5 inhibitors)


RN 251473-42-4 CAPLUS

CN 1-Piperazineethanol, 4-[[4-propoxy-3-[2,3,4,5-tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenyl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 251473-43-5 CAPLUS

CN 1-Piperazineethanol, 4-[[4-propoxy-3-[2,3,4,5-tetrahydro-3,5-dimethyl-1-(2-methylpropyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenyl]sulfonyl]-(9CI) (CA INDEX NAME)



GI



I

AB 8-Phenylxanthines I [R1, R2, R3 = H, alkenyl, alkynyl, cycloalkyl, alkylcarbamoyl, alkyl, etc.; R4R5N = 3 to 7-membered ring comprising a total of from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur; R4 = alkenyl, alkynyl, cycloalkyl, mono- or dialkylamino, alkylcarbamoyl, aminocarboiminoyl, alkyl group; R5 = (CH2)nR7 wherein n = 0-4 and R7 represents a 3 to 7-membered ring comprising from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur; R6 = H, alkyl group; SO2NR4R5 group is in the 4 or 5 position on the Ph group], useful as phosphodiesterase 5 inhibitors, were prepared E.g., 3-benzyl-1-methyl-8-[5-morpholine-4-sulfonyl]-2-propoxyphenyl]-3,7-dihydropurine-2,6-dione was prepared

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT.

L6 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:511159 CAPLUS

DOCUMENT NUMBER: 131:157709

TITLE: Preparation of bicyclic pyridine and pyrimidine

derivatives as neuropeptide Y receptor antagonists

INVENTOR(S): Norman, Mark H.; Chen, Ning; Han, Nianhe; Liu, Longbin; Hurt, Clarence R.; Fotsch, Christopher H.; Jenkins, Tracy J.; Moreno, Ofir A.

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 469 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940091	A1	19990812	WO 1999-US2500	19990205
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6187777	B1	20010213	US 1999-246775	19990204
CA 2319275	A1	19990812	CA 1999-2319275	19990205
AU 9926590	A	19990823	AU 1999-26590	19990205
AU 747920	B2	20020530		
EP 1054887	A1	20001129	EP 1999-906756	19990205
EP 1054887	B1	20060412		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY			
JP 2003502272	T	20030121	JP 2000-530520	19990205
AT 323088	T	20060415	AT 1999-906756	19990205
PT 1054887	T	20060630	PT 1999-906756	19990205

ES 2257851	T3	20060801	ES 1999-906756	19990205
ZA 9900967	A	19990806	ZA 1999-967	19990208
US 6583154	B1	20030624	US 2000-640263	20000816
PRIORITY APPLN. INFO.:			US 1998-73927P	P 19980206
			US 1998-73981P	P 19980206
			US 1998-93482P	P 19980720
			US 1998-93577P	P 19980720
			US 1999-246775	A 19990204
			WO 1999-US2500	W 19990205

OTHER SOURCE(S): MARPAT 131:157709


IT 34771-39-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrrolopyridine and pyrrolopyrimidine derivs. as neuropeptide Y receptor antagonists)

RN 34771-39-6 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-phenyl- (9CI) (CA INDEX NAME)



GI



I

AB Title compds. [I; R = H, CH₃, (CH₃)₂CH, SCH₃, CH₃CH₂, NH₂, CF₃, NHCOC₆H₅, cyclopropyl, CH₂OH, (CH₃)₂CH₂CH₂, N(CH₃)₂, OCH₃, NHCH₃, NH(CH₂)₄NH₂; R₁ = NH, S, NCH₃, O; R₂ = H, COCH₃, C₆H₅, CH₃, CH₃CH₂; R₃ = NH₂, CH₃, NHC₆H₅, N(CH₂CH₃)₂, (CH₃CH₂)N(CH₂)₃CH₃, (CH₃)N(CH₂)₂NHCH₃, N(CH₃)CH(CH₃)CH(Ph)OH, (CH₃CH₂)NCH₂C(CH₃):CH₂, NHCH₂CF₃, NHCH₂CH₂C₆H₅, NH(CH₂)₃OCH₂CH₃, 4-ClC₆H₄, 4-CH₃OC₆H₅, 2-thienyl, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 1-piperazinyl, 3-pyridyl; R₄ = C₆H₅, 4-CH₃C₆H₄, 4-ClC₆H₄, (CH₃)₃C, 4-FC₆H₄, 3-HOC₆H₄, 2-pyridyl, cyclohexyl, 2-furyl, 2-FC₆H₄ 2-thienyl, 1-adamantyl, CH₃, 4-CH₃OC₆H₄; X = N, CH; etc.], pharmaceutical acceptable. salts, ester, solvate, and N-oxide are prepared and tested as neuropeptide Y receptor antagonists in the modulation of feeding behavior, obesity, diabetes, cancer, inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions. Thus, the title compound I (R = CH₃; R₁ = NH; X = N; R₂ = H; R₃ = N(CH₂CH₃)₂; R₄ = C₆H₅) was prepared

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:331961 CAPLUS

DOCUMENT NUMBER: 126:305588

TITLE: Preparation of 4-(dioxopurinylmethyl)phenylacetates

and analogs as hypolipemics

INVENTOR(S): Connell, Richard; Goldmann, Siegfried; Mueller, Ulrich; Lohmer, Stefan; Bischoff, Hilmar; Denzer, Dirk; Gruetzmann, Rudi; Wohlfeil, Stefan

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Eur. Pat. Appl., 69 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 764647	A1	19970326	EP 1996-114577	19960912
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 19535504	A1	19970327	DE 1995-19535504	19950925
US 5714494	A	19980203	US 1996-710503	19960918
JP 09216884	A	19970819	JP 1996-267691	19960919
CA 2186086	A1	19970326	CA 1996-2186086	19960920
			DE 1995-19535504	A 19950925

PRIORITY APPLN. INFO.:



OTHER SOURCE(S): MARPAT 126:305588

IT 189213-05-6P 189213-06-7P 189213-07-8P
189213-08-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-(dioxopurinylmethyl)phenylacetates and analogs as hypolipemics)



RN 189213-05-6 CAPLUS

CN Benzeneacetic acid, α -cyclopentyl-4-[[1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-6-[4-(trifluoromethyl)phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 189213-06-7 CAPLUS



CN Benzeneacetic acid, α -cyclopentyl-4-[[1,2,3,4-tetrahydro-6-(4-methoxyphenyl)-1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 189213-07-8 CAPLUS
 CN Benzeneacetic acid, α -cyclopentyl-4-[[6-[4-(dimethylamino)phenyl]-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 189213-08-9 CAPLUS
 CN Benzeneacetic acid, α -cyclopentyl-4-[[6-[4-(diethylamino)phenyl]-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI



II

AB RCH₂ZCHR₁C(:L)R₂ [I; R = xanthine moiety, e.g., II; R₁ = H, (cyclo)alkyl, Ph, heterocyclyl, etc.; R₂ = OH, SH, alkoxy, (di)alkylamino, etc.; R₃, R₄ = H, alkyl, aryl, etc.; R₅ = H, halo, alkyl, aryl, etc.; L, T, V = O or S; Z = (un)substituted 1,4-phenylene] were prepared. Thus, 5,6-diamino-1,3-dimethyluracil was cyclocondensed with 4-MeC₆H₄CHO and the product N-alkylated by 4-(BrCH₂)C₆H₄CHR₁CO₂CMe₃ (R₁ = cyclopentyl) (preparation given) to give 4-(RCH₂)C₆H₄CHR₁CO₂CMe₃ (R = II, R₁ = cyclopentyl, R₃ = R₄ = Me, R₅ = C₆H₄Me-4, T = V = O). Data for biol. activity of I were given.

L6 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:748348 CAPLUS

DOCUMENT NUMBER: 126:31363

TITLE: Preparation of pyrrolodiazines as stabilizers for chlorine-containing polymer

INVENTOR(S): Wehner, Wolfgang; Friedrich, Hans-Helmut; Drewes, Rolf

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Can. Pat. Appl., 88 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2172692	A1	19960929	CA 1996-2172692	19960326
TW 426681	B	20010321	TW 1996-85103154	19960316
US 5770643	A	19980623	US 1996-618591	19960320
AU 9648232	A	19961010	AU 1996-48232	19960321
AU 702566	B2	19990225		
JP 08269279	A	19961015	JP 1996-95952	19960326
IL 117652	A	20000601	IL 1996-117652	19960326
NO 9601236	A	19960930	NO 1996-1236	19960327
ZA 9602437	A	19961001	ZA 1996-2437	19960327
BR 9601178	A	19980331	BR 1996-1178	19960328
US 6002004	A	19991214	US 1998-7196	19980114

PRIORITY APPLN. INFO.:

EP 1995-810204 A 19950328
US 1996-618591 A3 19960320

OTHER SOURCE(S): MARPAT 126:31363

IT 59119-44-7P 183373-54-8P


RL: MOA (Modifier or additive use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)

(preparation of pyrrolodiazines as stabilizers for chlorine-containing polymer)


RN 59119-44-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI)


(CA INDEX NAME)



RN 183373-54-8 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(1,1-dimethylethyl)phenyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; A = C(:X)NR₄C(:X)NR₅ or C(:X)NR₄C(YR₅):N; R₁ = H, alkyl, phenyl(alkyl), etc.; R₂, R₃ = H, alkyl, phenyl(alkyl), etc.; X = O, S, (alkyl)imino, etc.] were prepared. Thus, 4-amino-1,3-dimethyluracil was cyclocondensed with ClCH₂CO₂Me to give title compound II. Data for performance of I were given.

L6 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:721646 CAPLUS

DOCUMENT NUMBER: 125:330527

TITLE: Derivatives of pyrrolodiazine as stabilizers for polymers containing chlorine

INVENTOR(S): Wehner, Wolfgang; Friedrich, Hans-Helmut; Dröwes, Rolf

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 65 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

EP 736569	A1	19961009	EP 1996-810172	19960319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
TW 426681	B	20010321	TW 1996-85103154	19960316
US 5770643	A	19980623	US 1996-618591	19960320
AU 9648232	A	19961010	AU 1996-48232	19960321
AU 702566	B2	19990225		
JP 08269279	A	19961015	JP 1996-95952	19960326
IL 117652	A	20000601	IL 1996-117652	19960326
NO 9601236	A	19960930	NO 1996-1236	19960327
ZA 9602437	A	19961001	ZA 1996-2437	19960327
BR 9601178	A	19980331	BR 1996-1178	19960328
US 6002004	A	19991214	US 1998-7196	19980114
PRIORITY APPLN. INFO.:			EP 1995-810204	A 19950328
			US 1996-618591	A3 19960320


OTHER SOURCE(S): MARPAT 125:330527

IT 59119-44-7P 183373-54-8P

RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)
(preparation as heat stabilizer for chlorinated polymers)


RN 59119-44-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI)
(CA INDEX NAME)




RN 183373-54-8 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(1,1-dimethylethyl)phenyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)



GI



AB Pyrrolodiazines of specified structure are good stabilizers for polymers

containing Cl, especially PVC. Refluxing 1,3-dimethyluracil 1.0, chloroacetone 1.1, and NH₄OAc 2.0 mol in H₂O for 14 h gave 55% pyrrolodiazinedione I. Heating compounded PVC containing 1.0 phr I at 190° for 30 min gave PVC with yellowness index 42.0; vs. 143.4 after 25 min in the absence of I.

L6 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:533817 CAPLUS

DOCUMENT NUMBER: 121:133817

TITLE: Synthesis and Structure-Activity Relationships of Deazaxanthines: Analogs of Potent A1- and A2-Adenosine Receptor Antagonists

AUTHOR(S): Grahner, Bettina; Winiwarter, Susanne; Lanzner, Wolfgang; Mueller, Christa E.

CORPORATE SOURCE: Pharmazeutisches Institut, Eberhard-Karls-Universitaet Tuebingen, Tuebingen, D-72076, Germany

SOURCE: Journal of Medicinal Chemistry (1994), 37(10), 1526-34 CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 59119-44-7P 85102-50-7P 90994-81-3P

157119-66-9P 157119-67-0P 157119-68-1P


157119-69-2P 157119-70-5P 157119-72-7P

157119-74-9P 157119-76-1P 157119-77-2P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and adenosine antagonist activity of)


RN 59119-44-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 85102-50-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-1,3-dimethyl-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 90994-81-3 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 157119-66-9 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 3-methyl-6-phenyl- (9CI)
 (CA INDEX NAME)




RN 157119-67-0 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3,5-trimethyl-6-phenyl-
 (9CI) (CA INDEX NAME)




RN 157119-68-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-phenyl-3-propyl- (9CI)
 (CA INDEX NAME)




RN 157119-69-2 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-phenyl-1,3-dipropyl- (9CI)
 (CA INDEX NAME)




RN 157119-70-5 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-methyl-6-phenyl-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 157119-72-7 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-1,3-dimethyl-6-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 157119-74-9 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 157119-76-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3,5-trimethyl-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 157119-77-2 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3,5-trimethyl-6-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



GI



I

AB A set of 22 9-deazaxanthines and 3 7-deazaxanthines with various substituents in the 1-, 3-, 7- or 9-, and 8-positions was synthesized and investigated in A1 and A2a adenosine receptor binding assays at rat brain cortical membranes and rat brain striatal membranes, resp. 9-Deazaxanthines showed structure-activity relationships that were similar to those of xanthines. They were about equipotent to the corresponding xanthines at A2a adenosine receptors. 9-Deazaxanthines were generally at least 2-3-fold more potent than xanthines at A1 receptors and therefore exhibited higher A1 selectivities compared to the xanthines. 1,3-Dimethyl-8-(2-naphthyl)-9-deazaxanthine (I) showed high affinity ($K_i = 26$ nM) and selectivity for A1 adenosine receptors. A hydroxyl function at N-7 of 9-deazaxanthines was unfavorable for A1 and A2a receptor binding. 7-Deazaxanthines were considerably less potent compared to xanthines and to 9-deazaxanthines at both receptor subtypes.

L6 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1985:437449 CAPLUS

DOCUMENT NUMBER: 103:37449

TITLE: Further studies on the ring transformation of

pyrimido[5,4-e]-as-triazine 4-oxides to
pyrrolo[3,2-d]pyrimidines involving 1,3-dipolar
cycloaddition reaction


AUTHOR(S): Kanazawa, Hashime; Ichiba, Misuzu; Shimizu, Nobuyuki;
Tamura, Zenzo; Senga, Keitaro
CORPORATE SOURCE: Sch. Med., Keio Univ., Tokyo, 160, Japan
SOURCE: Journal of Organic Chemistry (1985), 50(14), 2413-16
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:37449

IT 96429-56-0P 96429-57-1P 96429-58-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and hydrolysis of)


RN 96429-56-0 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-7-carboxylic acid, 5-benzoyl-6-(4-
chlorophenyl)-2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-, ethyl ester
(9CI) (CA INDEX NAME)




RN 96429-57-1 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-7-carboxylic acid, 5-benzoyl-2,3,4,5-
tetrahydro-1,3-dimethyl-6-(4-methylphenyl)-2,4-dioxo-, ethyl ester (9CI)
(CA INDEX NAME)



RN 96429-58-2 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-7-carboxylic acid, 5-benzoyl-2,3,4,5-
tetrahydro-1,3-dimethyl-6-(4-nitrophenyl)-2,4-dioxo-, ethyl ester (9CI)
(CA INDEX NAME)




IT 96429-61-7P 96429-62-8P 96429-63-9P

96429-64-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 96429-61-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-7-carboxylic acid, 2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-6-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 96429-62-8 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-7-carboxylic acid, 6-(4-chlorophenyl)-2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 96429-63-9 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-7-carboxylic acid, 2,3,4,5-tetrahydro-1,3-dimethyl-6-(4-methylphenyl)-2,4-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 96429-64-0 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-7-carboxylic acid, 2,3,4,5-tetrahydro-1,3-dimethyl-6-(4-nitrophenyl)-2,4-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 96429-55-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, hydrolysis, and crystal structure of)

RN 96429-55-9 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-7-carboxylic acid, 5-benzoyl-2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-6-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



GI



AB The reaction of 3-alkyl(or aryl)pyrimidotriazinedione oxides I [R = Me, Et, 4-R₁C₆H₄ (R₁ = H, Cl, Me, NO₂)] with PhC.tplbond.CCO₂Et in PhMe gave the unexpected pyrrolopyrimidinediones II. The structures of II were supported by spectral data as well as by chemical means and were confirmed by

single-crystal x-ray diffractions. On the other hand, the reaction of I (R = H) with PhC.tplbond.CCO2Et yielded pyrrolopyrimidinedioneIII.

L6 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1984:455047 CAPLUS

DOCUMENT NUMBER: 101:55047

TITLE: Pyrimidine derivatives and related compounds. Part 47. A new synthesis of xanthines and pyrrolo[3,2-d]pyrimidines by intramolecular cyclization of 6-substituted 5-nitrouracil derivatives

AUTHOR(S): Hirota, Kosaku; Sugiyama, Tadashi; Kitade, Yukio; Senda, Shigeo; Maki, Yoshifumi

CORPORATE SOURCE: Gifu Coll. Pharm., Gifu, 502, Japan

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1984), (4), 583-8
CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 101:55047


IT 85102-46-1P 85102-47-2P 85102-48-3P

85102-49-4P 85102-50-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)


RN 85102-46-1 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 85102-47-2 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-1,3-dimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 85102-48-3 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-6-(4-methoxyphenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 85102-49-4 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-chlorophenyl)-5-hydroxy-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 85102-50-7 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-1,3-dimethyl-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



IT 90994-81-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 90994-81-3 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




IT 1036-65-3P 59119-44-7P 59119-46-9P
 75997-48-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by reduction of hydroxy derivative)


RN 1036-65-3 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-methoxyphenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 59119-44-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI)
(CA INDEX NAME)




RN 59119-46-9 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 75997-48-7 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-chlorophenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




GI




I




II




III



IV



V



VI

AB 6-(Arylalkylamino)uracils I ($R = R_1 = H$, $R_2 = H$, Me, OMe, Cl; $R = R_2 = H$, $R_1 = Me$; $R = Me$, $R_1 = R_2 = H$) were prepared in 66-86% yield by substitution of 6-chloro-1,3-dimethyl-5-nitro-uracil with $RNHCH(R_1)C_6H_4R_2$ -p in the presence of Et₃N. On refluxing in DMF I ($R = R_1 = H$, $R_2 = H$, Me, OMe, Cl) cyclized to the corresponding xanthines II in 39-47% yield. Reaction of Na salt III with alkyl and aralkyl halides in DMF at 80° for 2 h gave 6-alkyluracils IV ($R = H$, Ph, C₆H₄Me-p, C₆H₄OMe-p, C₆H₄Cl-p, α -C₁₀H₇, C₆H₄NO₂-o, CO₂Et, COMe, CN). IV ($R = aryl$) underwent base-catalyzed cyclization to give deazaxanthines V ($R = Ph$, p-MeC₆H₄, p-MeOC₆H₄, p-ClC₆H₄, α -C₁₀H₇, $R_1 = OH$) whereas IV ($R = CO_2Et$, COMe, CN) with Et₃N gave the corresponding 6-vinyluracils VI. V were prepared directly from III by treatment with aralkyl chlorides in the presence of K₂CO₃ in dry DMF. Deoxygenation of V on heating in DMF gave V (R as before, $R_1 = H$) in 84-95% yield.

L6 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:143362 CAPLUS

DOCUMENT NUMBER: 98:143362

TITLE: A facile synthesis of 7-hydroxy-9-deazaxanthines

AUTHOR(S): Hirota, Kosaku; Sugiyama, Tadashi; Kitade, Yukio;

Senda, Shigeo; Maki, Yoshifumi

CORPORATE SOURCE: Gifu Coll., Gifu, 502, Japan

SOURCE: Synthesis (1982), (12), 1097-9

CODEN: SYNTBF; ISSN: 0039-7881

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 98:143362


IT 59119-44-7P 85102-46-1P 85102-47-2P

85102-48-3P 85102-49-4P 85102-50-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59119-44-7 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI)
(CA INDEX NAME)




RN 85102-46-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 85102-47-2 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-1,3-dimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 85102-48-3 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-6-(4-methoxyphenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 85102-49-4 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-chlorophenyl)-5-hydroxy-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 85102-50-7 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 5-hydroxy-1,3-dimethyl-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




GI



I



II



III

AB Aralkylation of uracil salt I with RCH_2Cl ($R = Ph, p\text{-tolyl}, p\text{-anisyl}, p\text{-ClC}_6H_4, 1\text{-naphthyl}$) gave 86-91% nitrouracils II, which cyclized to give 80-93% hydroxydeazaxanthines III.

L6 ANSWER 21 OF 30. CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:89294 CAPLUS

DOCUMENT NUMBER: 98:89294

TITLE: Syntheses and properties of 3-hydroxy-4,6-dimethylpyrrolo[3,2-d]pyrimidine-5,7(4H,6H)-dione (9-hydroxy-9-deazatheophylline) derivatives

AUTHOR(S): Yoneda, Fumio; Motokura, Miyuki; Kamishimoto, Mutsuko; Nagamatsu, Tomohisa; Otagiri, Masaki; Uekama, Kaneto; Takamoto, Masayuki

CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, 862, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1982), 30(9),

3187-96

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE:

Journal

LANGUAGE:

English

IT 79834-64-3P 79834-65-4P 79834-66-5P

79834-67-6P 79834-68-7P 84637-38-7P


84637-39-8P 84637-40-1P 84637-41-2P

84637-42-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 79834-64-3 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-methoxy-1,3,5-trimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 79834-65-4 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-methoxy-1,3,5-trimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 79834-66-5 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-methoxy-6-(4-methoxyphenyl)-1,3,5-trimethyl- (9CI) (CA INDEX NAME)




RN 79834-67-6 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-chlorophenyl)-7-methoxy-1,3,5-trimethyl- (9CI) (CA INDEX NAME)




RN 79834-68-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-fluorophenyl)-7-methoxy-1,3,5-trimethyl- (9CI) (CA INDEX NAME)




RN 84637-38-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-(benzoyloxy)-1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 84637-39-8 CAPLUS

CN Benzoic acid, 4-chloro-, 2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-6-phenyl-1H-pyrrolo[3,2-d]pyrimidin-7-yl ester (9CI) (CA INDEX NAME)




RN 84637-40-1 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-(benzoyloxy)-6-(4-chlorophenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 84637-41-2 CAPLUS

CN Benzoic acid, 4-chloro-, 6-(4-chlorophenyl)-2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-7-yl ester (9CI) (CA INDEX NAME)



RN 84637-42-3 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-(acetyloxy)-1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




IT 59119-48-1P 63711-19-3P 63711-20-6P

79834-62-1P 79834-63-2P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, methylation and arylation of)

RN 59119-48-1 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-hydroxy-1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 63711-19-3 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-hydroxy-1,3-dimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 63711-20-6 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-hydroxy-6-(4-methoxyphenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 79834-62-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-chlorophenyl)-7-hydroxy-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 79834-63-2 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-fluorophenyl)-7-hydroxy-1,3-dimethyl- (9CI) (CA INDEX NAME)



GI



I



II

AB Treatment of I with aryl aldehydes in the presence of piperidine results in condensation to the 5-nitro-6-styryluracil derivs., followed by intramol. cyclization including piperidine-catalyzed oxidation-reduction to give the corresponding title derivs. (II; R = aryl; R1 = H) in a single step. II (R = aryl; R1 = Me, aroyl) were also prepared

L6 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:4515 CAPLUS

DOCUMENT NUMBER: 98:4515

TITLE: New syntheses of pyrido[3,2-d]pyrimidines. (1)

AUTHOR(S): Senga, Keitaro; Fukami, Kiyoko; Kanazawa, Hashime; Nishigaki, Sadao

CORPORATE SOURCE: Sch. Med., Keio Univ., Tokyo, 160, Japan

SOURCE: Journal of Heterocyclic Chemistry (1982), 19(4), 805-8

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 83848-77-5P


RL: SPN (Synthetic preparation); PREP (Preparation).
(preparation of)

RN 83848-77-5 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-7-carboxaldehyde, 2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-6-phenyl- (9CI) (CA INDEX NAME)



GI



III

AB New synthetic routes to pyrido[3,2-d]pyrimidines starting with 5-amino-1,3,6-trimethyluracil (I) or 1,3,6-trimethyl-5-nitrouracil (II) are described. Thus, condensation of I with arylaldehydes gave 5-arylideneamino-1,3,6-trimethyluracils, which upon heating with Me₂NCH(OMe)₂ afforded the pyridopyrimidinediones III [R = (un)substituted phenyl] via 5-arylideneamino-1,3-dimethyl-6-(2-dimethylaminovinyl)uracils. Reaction of II with PhCH₂CHO in the presence of base yielded III (R = Ph) and its 5-oxide.

L6 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1982:6463 CAPLUS

DOCUMENT NUMBER: 96:6463

TITLE: New synthesis of 1,3-dimethyl-7-hydroxypyrrolo[3,2-d]pyrimidine-2,4(1H,3H)-diones (9-hydroxy-9-deazatheophyllines)

AUTHOR(S): Yoneda, Fumio; Motokura, Miyuki; Otagiri, Masaki

CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, 862, Japan

SOURCE: Chemistry Letters (1981), (9), 1273-6

CODEN: CMLTAG; ISSN: 0366-7022

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 59119-48-1P 63711-19-3P 63711-20-6P


79834-62-1P 79834-63-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, with Me iodide and DMF)


RN 59119-48-1 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-hydroxy-1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 63711-19-3 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-hydroxy-1,3-dimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 63711-20-6 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-hydroxy-6-(4-methoxyphenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 79834-62-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-chlorophenyl)-7-hydroxy-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 79834-63-2 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-fluorophenyl)-7-hydroxy-1,3-dimethyl- (9CI) (CA INDEX NAME)




IT 79834-64-3P 79834-65-4P 79834-66-5P
 79834-67-6P 79834-68-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 79834-64-3 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-methoxy-1,3,5-trimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 79834-65-4 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-methoxy-1,3,5-trimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 79834-66-5 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-methoxy-6-(4-methoxyphenyl)-1,3,5-trimethyl- (9CI) (CA INDEX NAME)




RN 79834-67-6 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-chlorophenyl)-7-methoxy-1,3,5-trimethyl- (9CI) (CA INDEX NAME)




RN 79834-68-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-fluorophenyl)-7-methoxy-1,3,5-trimethyl- (9CI) (CA INDEX NAME)



GI



AB Treatment of 5-nitro-1,3,6-trimethyluracil with aryl aldehydes in the presence of piperidine causes the condensation to the 5-nitro-6-styryluracil derivs., followed by the intramol. cyclization including piperidine-catalyzed oxidation-reduction to give the corresponding 9-hydroxy-9-deazatheophylline derivs. I (R = Ph, 4-MeC₆H₄, 4-MeOC₆H₄, 4-ClC₆H₄, 4-FC₆H₄) in a single step. Some properties of these compds. are discussed.

L6 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1981:15676 CAPLUS

DOCUMENT NUMBER: 94:15676

TITLE: Syntheses of 9-deazatheophyllines and 6-deoxy-9-deazatheophyllines

AUTHOR(S): Nishigaki, Sadao; Kanamori, Yukako; Senga, Keitaro

CORPORATE SOURCE: Sch. Med., Keio Univ., Tokyo, 160, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1980), 28(5), 1636-41

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 59119-44-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and chlorination of)

RN 59119-44-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




IT 1036-65-3P 34771-41-0P 75997-48-7P

75997-49-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 1036-65-3 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-methoxyphenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 34771-41-0 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-bromophenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 75997-48-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-chlorophenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)






RN 75997-49-8 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(3,4-dichlorophenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)



GI



AB The reaction of the uracils I (R = H, 4-Br, 4-Cl, 3,4-Cl₂, 4-MeO) with Na₂S₂O₄ in HCO₂H gave the corresponding 8-aryl-9-deazatheophyllines II. The reaction of II (R = H) with POCl₃ gave the deazatheophylline III (R₁ = Cl), whereas the reaction of II (R = H) with POCl₃ in the presence of arylamines provided the corresponding III (R₁ = PhNH, 4-BrC₆H₄NH, 4-MeOC₆H₄NH) in a single step.

L6 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1979:611369 CAPLUS

DOCUMENT NUMBER: 91:211369

TITLE: New synthesis of pyrrolo[3,2-d]pyrimidines (9-deazapurines) by the 1,3-dipolar cycloaddition reaction of fervenulin 4-oxides with acetylenic esters
AUTHOR(S): Senga, Keitaro; Ichiba, Misuzu; Nishigaki, Sadao
CORPORATE SOURCE: Sch. Med., Keio Univ., Tokyo, 160, Japan
SOURCE: Journal of Organic Chemistry (1979), 44(22), 3830-4
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 59119-44-7P 71411-56-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 59119-44-7 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI)
(CA INDEX NAME)




RN 71411-56-8 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-7-carboxylic acid, 2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-6-phenyl-, methyl ester (9CI) (CA INDEX NAME)



GI



AB 1,3-Dipolar cycloaddn. reaction of fervenulin 4-oxides I (R = Ph, Me, Et, H) with MeO₂CC.tplbond.CCO₂Me and HC.tplbond.CCO₂Me gave a variety of pyrrolo[3,2-d]pyrimidines (9-deazapurines) in a new synthetic route.

L6 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1978:152556 CAPLUS

DOCUMENT NUMBER: 88:152556

TITLE: 9-Deazapurines from pyrimido[4,5-b][1,4]thiazines

AUTHOR(S): Fenner, Helmut; Motschall, Annegrete

CORPORATE SOURCE: Inst. Pharm., Freie Univ. Berlin, Berlin, Fed. Rep. Ger.

SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1978), 311(2), 153-61

CODEN: ARPMAS; ISSN: 0365-6233

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 88:152556

IT 34771-42-1P 66127-45-5P 66127-46-6P


66127-47-7P 66127-48-8P 66127-49-9P

66127-50-2P 66127-51-3P 66127-52-4P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 34771-42-1 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6,7-diphenyl- (9CI) (CA INDEX NAME)




RN 66127-45-5 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-nitrophenyl)-1,3-


bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 66127-46-6 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-methoxyphenyl)-1,3-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 66127-47-7 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-methyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 66127-48-8 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3,7-trimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 66127-49-9 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-methyl-6-phenyl-1,3-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 66127-50-2 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6,7-diphenyl- (9CI) (CA INDEX NAME)




RN 66127-51-3 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-diethyl-6,7-diphenyl- (9CI) (CA INDEX NAME)




RN 66127-52-4 CAPLUS
 CN [7,7'-Bi-1H-pyrrolo[3,2-d]pyrimidine]-2,2',4,4' (3H,3'H,5H,5'H)-tetrone, 6,6'-bis(4-methoxyphenyl)-1,1',3,3'-tetramethyl- (9CI) (CA INDEX NAME)



GI



I



II

AB Pyrrolopyrimidinediones I (R = H, Me, CH₂Ph; R₁ = Me, Ph, 4-O₂NC₆H₄, 4-MeOC₆H₄; R₂ = H, Me, Ph) were obtained in 70-80% yield by thermal S extrusion from II. The 7-di-Me analogs of II (R = H, Me, R₁ = R₂ = Me) did not undergo the S extrusion. II were obtained by treating 6-thiouramils with halo compds.

L6 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1977:535239 CAPLUS

DOCUMENT NUMBER: 87:135239

TITLE: Pyrimidine derivatives and related compounds. XXIX. Photoreductive cyclization of 5-nitro-6-styryl (or anilino)uracil derivatives to pyrrolo[3,2-d]pyrimidine and alloxazine derivatives

AUTHOR(S): Senda, Shigeo; Hirota, Kosaku; Suzuki, Mikio; Takahashi, Mikio

CORPORATE SOURCE: Gifu Coll. Pharm., Gifu, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1977), 25(4), 563-8

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 87:135239


IT 1036-65-3P 59119-44-7P 59119-46-9P

59119-48-1P 63711-19-3P 63711-20-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)


RN 1036-65-3 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-methoxyphenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 59119-44-7 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 59119-46-9 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 59119-48-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-hydroxy-1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 63711-19-3 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-hydroxy-1,3-dimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 63711-20-6 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-hydroxy-6-(4-methoxyphenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




GI




I




II



III



IV



V

AB Irradiation of 1,3-dimethyl-5-nitro-6-styryluracils I (R = H, Me, MeO) principally gave 1,3-dimethyl-6-phenylpyrrolo[3,2-d]pyrimidines II in 8-16% yields. Irradiation of 6-anilino-5-nitrouracils III (R1 = Me, R2 = H; R1 = H, R2 = H, Me) gave alloxazines IV (R1 = H, Me) and isoxalloxazine (V) in 14-18% yields.

L6 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1976:164716 CAPLUS

DOCUMENT NUMBER: 84:164716

TITLE: Photoreductive cyclization of 5-nitro-6-styryl (or anilino)uracil derivatives to pyrrolo[3,2-d]pyrimidine and alloxazine derivatives

AUTHOR(S): Senda, Shigeo; Hirota, Kosaku; Takahashi, Mikio

CORPORATE SOURCE: Gifu Coll. Pharm., Gifu, Japan

SOURCE: Heterocycles (1976), 4(3), 461-5

CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 84:164716

IT 1036-65-3P 59119-44-7P 59119-46-9P


59119-48-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 1036-65-3 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-methoxyphenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 59119-44-7 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 59119-46-9 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 59119-48-1 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 7-hydroxy-1,3-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)



GI



AB Irradiation (high pressure mercury lamp) of styryluracils I (R = H, Me, OMe) in Me₂CHOH caused photoreductive cyclization to give 3-8% benzoquinazolines II and 8-16% pyrrolopyrimidines III (R's as above). In C₆H₆, irradiation of I (R = H) did not give III (R = H), but instead, 10% II (R = H) and 8% pyrrolopyrimidine IV (R = H). Analogously, photolysis of V (R¹ = Me, R² = H; R¹ = H, R² = Me) in MeOH gave 15% alloxazine VI (R¹ = Me) and 14% isoalloxazine VII. The 5-nitroso analog of V (R¹ = R² = H) was irradiated to give 77% alloxazine VI (R¹ = H).

L6 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1972:14486 CAPLUS

DOCUMENT NUMBER: 76:14486

TITLE: Pyrrolo[3,2-d]pyrimidine from pyrimido[4,5-b][1,4]thiazine

AUTHOR(S): Fenner, Helmut; Motschall, Harald

CORPORATE SOURCE: Fachbereich Pharm., Freie Univ., Berlin-Dahlem, Fed. Rep. Ger.

SOURCE: Tetrahedron Letters (1971), (44), 4185-8

CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: German


IT 34771-39-6P 34771-40-9P 34771-41-0P

34771-42-1P


RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of).

RN 34771-39-6 CAPLUS


CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-phenyl- (9CI) (CA INDEX NAME)




RN 34771-40-9 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-bromophenyl)- (9CI)
 (CA INDEX NAME)



RN 34771-41-0 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-bromophenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 34771-42-1 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-6,7-diphenyl- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB The reaction of phenacyl halides with 5-amino-6-mercapto-2,4-(1H,3H)-pyrimidinedione (I) gave different amts. of II and III under different conditions and II was thermally converted to III. Thus, treating I with PhCOCH₂Cl or p-BrC₆H₄COCH₂Br under N in buffered EtOH-H₂O gave II (R = H or Br). Heating the phenacyl halides at 60° with I in DMF gave II and III. Heating II 3-4 hr at 130° in DMF gave III quant. 7-Substituted II also underwent this reaction.

L6 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1965:66502 CAPLUS

DOCUMENT NUMBER: 62:66502

ORIGINAL REFERENCE NO.: 62:11807a-b

TITLE: New syntheses of pyrrolo[2,3-d]- and

pyrrolo[3,2-d]pyrimidines

AUTHOR(S): Taylor, Edward C.; Garcia, Edward E.

CORPORATE SOURCE: Princeton Univ., Princeton, NJ

SOURCE: Journal of Organic Chemistry (1965), 30(2), 655-7

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 62:66502

IT 1036-65-3P, 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)dione,

6-(p-methoxyphenyl)-1,3-dimethyl- 1040-37-5P,


1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)dione, 6-[p-(dimethylamino)phenyl]-
1,3-dimethyl-

RL: PREP (Preparation)

(preparation of)


RN 1036-65-3 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-(4-methoxyphenyl)-1,3-
dimethyl- (9CI) (CA INDEX NAME)



RN 1040-37-5 CAPLUS

CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-(dimethylamino)phenyl]-
1,3-dimethyl- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB Condensation of 1,3-dimethyl-6-anilinouracil with phenacylpyridinium
bromide gave 1,3-dimethyl-6,7-diphenyl-7H-2,4-(1H,3H)-pyrrolo[2,3-
d]pyrimidinedione (I). This condensation may be useful in the preparation of
further 6,7-disubstituted derivs. When 1,3-dimethyl-5-nitro-6-(p-
methoxystyryl)uracil and 1,3-dimethyl-5-nitro-6-[(p-
dimethylamino)styryl]uracil were refluxed with triethyl phosphite they
afforded the pyrrolo[3,2-d]pyrimidines (II, R = C6H4OMe-p and C6H4NMe2-p).

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
163.53	341.24

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-23.40	-23.40

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 08:57:56 ON 16 FEB 2007